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ABSTRACT 
 
Several successful pathogens evade host defenses resulting in the 
establishment of persistent and chronic infections. One such pathogen, 
Porphyromonas gingivalis, induces chronic low-grade inflammation associated 
with local inflammatory oral bone loss and systemic inflammation manifested as 
atherosclerosis. The pathogenic mechanisms contributing to P. gingivalis evasion 
of host immunity and chronic inflammation are not well defined.  
 
P. gingivalis evades host immunity at Toll-like receptor (TLR)-4 through 
expression of an atypical lipopolysaccharide (LPS) that contains lipid A species 
that exhibit TLR4 agonist or antagonist activity or fail to activate TLR4. By 
utilizing a series of P. gingivalis lipid A mutants we demonstrated that expression 
of antagonist lipid A structures resulted in weak induction of proinflammatory 
mediators. Moreover, expression of antagonist lipid A failed to activate the 
inflammasome, which correlated with increased bacterial survival in 
  
 
 vii
macrophages. Oral infection of atherosclerotic prone apolipoprotein E (ApoE) 
deficient mice with the antagonist lipid A strain resulted in vascular inflammation 
characterized by macrophage accumulation and atherosclerosis progression. In 
contrast, a P. gingivalis strain expressing exclusively agonist lipid A augmented 
levels of proinflammatory mediators and activated the inflammasome in a 
caspase-11 dependent manner, resulting in host cell lysis and decreased 
bacterial survival. ApoE deficient mice infected with the agonist lipid A strain 
exhibited diminished vascular inflammation.  Notably, the ability of P. gingivalis to 
induce local inflammatory oral bone loss was independent of lipid A expression, 
indicative of distinct mechanisms for induction of local versus systemic 
inflammation by this pathogen.  
 
We next investigated the role of TLRs and lipid A on bacterial trafficking by the 
autophagic pathway. Originally characterized as a cell autonomous pathway for 
recycling damaged organelles and proteins, autophagy is now recognized to play 
a critical role in innate defense and release of the proinflammatory cytokine 
interleukin (IL)-1β. We demonstrated that P. gingivalis suppresses the 
autophagic pathway in macrophages for pathogen survival and intercepts 
autophagy-mediated IL-1β release. P. gingivalis-mediated suppression of 
autophagy was independent of lipid A expression but partially dependent on 
TLR2 signaling. Collectively, our results indicate that P. gingivalis evasion of 
innate immunity plays a role in chronic inflammation.   
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Chapter 1. Introduction
Porphyromonas gingivalis induction of local and systemic inflammation  
A hallmark of chronic infection with Porphyromonas gingivalis is the induction of 
periodontitis; an inflammatory disease that leads to the destruction of supporting 
tissues of teeth, such as the gingiva, and resorption of the underlying alveolar 
bone (Oliver et al.,1998; Pihlstrom et al.,2005; Hayashi et al.,2010a; Abe et 
al.,2012). In states of periodontal health, the gingiva are firmly attached to the 
root surface (Lockhart et al.,2012a). However, immune recognition of periodontal 
pathogens results in progressive inflammation consistent of an immune cell 
infiltrate and production of inflammatory mediators (Shaik-Dasthagirisaheb et 
al.,2014). During acute or active stages of periodontal disease, there is an initial 
influx of neutrophils. As inflammation progresses to a more chronic state, the 
lesion becomes composed of a cellular infiltrate that is predominately monocytic 
(Hayashi et al.,2010a). Monocytic cells become activated macrophages, which 
further accelerate bone resporption through differentiation into osteoclast and 
production of tissue damaging proinflammatory cytokines (Adamopoulos et 
al.,2006). Monocyte chemoattractant protein-1 (MCP-1) has been suggested to 
have an important role in the activation and recruitment of inflammatory and 
immune cells in periodontal disease (Kurtiş et al.,2005). Furthermore, additional 
pro inflammatory mediators such as IL-8 and IL-1β have been detected In 
gingival crevicular fluid from periodontal patients (Gamonal et al.,2000).  
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Although there are over 500 bacterial species in the oral cavity, only a few 
bacteria, such as P. gingivalis, are implicated in the progression of periodontal 
disease (Gibson et al.,2006). In addition to P. gingivalis, organisms such as 
Treponema denticola and Tannerella forsythia comprise a “red complex” which 
was traditionally accepted to be the root of the destructive inflammation present 
in the oral cavity (Hajishengallis, 2011). However, it has been recently revealed 
that induction of periodontitis is actually more complex and involves the entire 
microbial community present in the oral cavity (Hajishengallis, 2014). In a mouse 
model of periodontitis, P. gingivalis was shown to be in low-abundance, only 
comprising <.01% of the total bacterial count (Hajishengallis et al.,2011). This 
study revealed that at this low colonization level, P. gingivalis induces a shift in 
the oral microbiota, known as dysbiosis, resulting in alterations in the relative 
abundances of individual components of the bacterial community. Therefore, 
from murine studies, it is now thought that P. gingivalis orchestrates rather than 
directly causes inflammatory bone loss. Inflammation is largely mediated by 
“pathobionts” which are commensals that under disrupted homeostasis (i.e. 
during P. gingivalis infection) have the potential to deregulated inflammation and 
disease (Hajishengallis et al.,2012; Abusleme et al.,2013). It is important to note 
that although the tooth-associated biofilm is required to induce periodontitis, it is 
also the host inflammatory response to this microbial challenge that ultimately 
causes destruction of the periodontium (Hajishengallis, 2014). 
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In addition to inflammation induced at the initial site of infection, P. gingivalis has 
been associated with systemic diseases such as diabetes, pre-term birth, 
pancreatic cancer, and cardiovascular disease (Tonetti, 2009; Bohnstedt et 
al.,2010; Michaud et al.,2013). Given the high incidence of periodontitis and 
cardiovascular disease and their economic cost to society, understanding the link 
between these two diseases has tremendous importance (Lockhart et al.,2012b). 
In the US more than 47%  (~100 million) of adults have periodontitis (Hayashi et 
al.,2010a; Eke et al.,2012). Cardiovascular diseases are one of the leading 
causes of mortality worldwide, accounting for 16.7 million deaths each year 
(Hansson and Hermansson, 2011; Lockhart et al.,2012b).  
 
Like periodontitis, cardiovascular disease is a chronic inflammatory disorder and 
involves the slow progression of chronic inflammation of the blood vessels, 
known as atherosclerosis. Atherosclerosis begins with a dysfunctional 
endothelium that results in recruitment of a number of immune cells, such as 
macrophages and T cells (Cole et al.,2010a). Immune cells subsequently 
become activated by ligands present in the vasculature, resulting in the 
production a number of pro inflammatory mediators that further propagate 
inflammation (Feghali and Wright, 1997; Hajishengallis and Lambris, 2011).  The 
resulting abundance of unwarranted inflammation contributes to excessive tissue 
damage, which characterizes chronic inflammatory diseases like atherosclerosis 
(Tabas and Glass, 2013).  
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Infection and atherosclerosis progression 
Originally atherosclerosis was considered a disorder involving lipid accumulation 
in the arterial wall; however, it is now well recognized that disease progression is 
complex, with significant involvement of the immune response (Edfeldt et 
al.,2002; Hansson and Libby, 2006; Hansson and Hermansson, 2011). Cells that 
comprise the immune response become activated through engagement of 
receptors that decorate their outer membrane; the most extensively studied are 
the Toll-like receptors (TLRs) (Akira et al.,2001). TLRs are uniquely equipped to 
provide host surveillance and the first line of defense to infection through 
recognition of conserved pathogen associated molecular patterns (PAMPs) 
(Takeda and Akira, 2004; Kawai and Akira, 2006). Receptors in the TLR family 
recognize specific PAMPs and upon ligand recognition, TLRs orchestrate an 
innate immune defense against invading pathogens. In addition to exogenous 
pathogen derived ligands, it is now widely recognized that endogenous ligands 
can activate TLRs (Hansson and Hermansson, 2011). In context of the 
vasculature, oxidized LDL has been reported to engage TLRs on monocytic cells, 
resulting in lipid laden foam cells that characterize the earliest stages of lesion 
development (Hansson and Hermansson, 2011). Macrophages in the intima 
upregulate scavenger receptors, which can also take up oxidized LDL, thereby 
providing an additional mechanism for intracellular cholesterol accumulation and 
foam cell formation in atherosclerotic lesions (Hansson and Hermansson, 2011).  
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Although endogenous ligands have been reported to contribute to 
atherosclerosis progression, there are now a large number of different infectious 
agents associated with increased risk of cardiovascular disease (Rosenfeld and 
Campbell, 2011). Pathogens such as Chlamydia pneumoniae, Helicobacter pylori 
and P. gingivalis have been identified within human atherosclerotic plaques (Shor 
et al.,1992; Kuo et al.,1993; Farsak et al.,2000; Haraszthy et al.,2000; Ameriso et 
al.,2001; Latsios et al.,2004; Kozarov et al.,2005; Kaplan et al.,2006), suggesting 
that infectious agents are capable of gaining access to the vasculature. These 
observations have been supported by multiple epidemiological studies that have 
established associations between cardiovascular disease and markers of 
infection (Rosenfeld and Campbell, 2011).  
 
Due to these reports, in the period between 2003 - 2006, four separate large 
clinical trials were designed to treat coronary artery disease patients with 
antibiotics in order to alleviate disease progression (O'Connor et al.,2003; 
Cannon et al.,2005; Grayston et al.,2005; Jespersen et al.,2006). The results 
from these trials, each of which enrolled over 4,000 patients with coronary artery 
disease, reported no significant long-term benefit of treatment of antibiotics in 
patients with established disease. Following the report of these separate studies, 
interest in further examining the link between infection and cardiovascular 
disease significantly declined.  
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It is important to note that is has been difficult to establish a causative 
relationship between these two diseases in a clinical setting for a number of 
reasons (Lockhart et al.,2012b; Reyes et al.,2013b). First, the antibiotics chosen 
for these clinical trials were targeted specifically to Chlamydia pneumoniae and 
not to other infectious agents that have been linked to an increased risk of 
cardiovascular disease. Furthermore, it is difficult to target an individual factor 
contributing to the inflammation since the inflammatory response in the lesion is 
multifactorial (Keizer, 2012; Raman et al.,2013). Finally, patients enrolled in 
these clinical trials had advanced, chronic inflammation with “end-stage disease” 
(Rosenfeld and Campbell, 2011).  The early phases of atherosclerosis involve 
injury to the endothelium, an event that is likely missed since it is asymptomatic 
(Vita and Loscalzo, 2002). It is plausible that antibiotics would be beneficial in 
patients with early atherosclerosis, however these clinical trials would be difficult 
to design.  
 
Analogous to the clinical trials performed with antibiotics, multiple studies have 
evaluated the impact of periodontal treatment, with or without antimicrobial 
therapy on systemic inflammation or endothelial dysfunction, and have shown 
mixed results (extensively reviewed by (Kebschull et al.,2010). Current clinical 
studies are being more appropriately designed in order to examine the impact of 
oral pathogens in cardiovascular disease progression. In a recent study 
published by Desvarieux et al, changes in periodontal status, assessed both 
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clinically and microbiologically, were associated with progression of carotid 
atherosclerosis (Desvarieux et al.,2013). This report found that the relative 
predominance of bacteria, traditionally considered causally related to periodontal 
disease, were the most closely linked to atherosclerosis progression. These 
results provided the first evidence that improvement in periodontal status is 
related to a decreased progression of carotid atherosclerosis in humans, thereby 
strengthening the role of pathogens, especially those associated with periodontal 
disease, to clinical cardiovascular disease. 
 
Periodontal disease as a risk factor for atherosclerosis   
The role of periodontitis in exacerbating atherosclerosis is an attractive area of 
research due to the ability of periodontal pathogens to enter circulation following 
physical perturbation of the gingiva (Reyes et al.,2013b). In addition to the 
multiple epidemiological studies that provide evidence for periodontal disease as 
a risk factor for cardiovascular disease, serological studies link elevated 
periodontal bacteria antibody titers to atherosclerotic vascular disease (Beck et 
al.,1996; Genco, 1996; Morrison et al.,1999; Offenbacher et al.,1999; Amar et 
al.,2003; Gibson et al.,2006; Pussinen et al.,2007; Gibson et al.,2008; Hayashi et 
al.,2010a). Case control studies have substantiated the correlation between 
cardiovascular disease and periodontal disease after adjusting for confounding 
factors (Pihlstrom et al.,2005; Seinost et al.,2005). Results from the Oral 
Infections and Vascular Disease Epidemiology Study revealed an association 
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between periodontal pathogens and atherosclerosis (Wu et al.,2000; Desvarieux 
et al.,2005). Although these studies support a positive association between 
periodontal disease and cardiovascular disease, others have not (Kebschull et 
al.,2010). Therefore, there currently remains controversy on whether there is a 
clinically significant association between these two diseases (Lockhart et 
al.,2012a).  
 
Both direct and indirect mechanisms have been proposed for how periodontal 
pathogens may accelerate atherosclerosis progression (Reyes et al.,2013b).  
Oral infection has been proposed to play an indirect role through the production 
of cytokines or acute phase proteins that enter systemic circulation and reach 
sites distant from initial infection (Glurich et al.,2002). A number of periodontal 
pathogens have been detected in human atheromas by PCR, suggesting that 
these pathogens are able to gain access to the vasculature. This finding led to 
direct activation of local immune responses in atherosclerotic lesions as a 
proposed mechanism for pathogen-mediated atherosclerosis progression. 
(Rosenfeld and Campbell, 2011).  Culturing viable microorganisms from human 
atheromas has proven to be difficult (Weiss et al.,1996; Ieven and Hoymans, 
2005). However, one study has reported the viability of both Actinobacillus 
actinomycetemcomitans and P. gingivalis in human atherosclerotic plaque 
(Kozarov et al.,2005).  
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Periodontal pathogens likely gain entry to the bloodstream from routine dental 
procedures or everyday oral activities, such as tooth brushing (Forner et al.,2006; 
Tomás et al.,2012). It has been proposed that patients with periodontal disease 
most likely have higher levels of bacteremia from every day oral activities (Reyes 
et al.,2013b).  A comprehensive search of the literature provides a list of 275 
bacterial species that have been identified in blood cultures after routine daily 
events or dental procedures (Bahrani-Mougeot et al.,2008; Lockhart et al.,2008), 
supporting the concept that the gingival sulcus in the main source and portal to 
the blood stream for oral bacterial species detected in the blood (Lockhart et 
al.,2012a). However, how periodontal pathogens may travel undetected in the 
bloodstream in order to reach systemic sites is unknown. One currently proposed 
mechanism is periodontal pathogens are able to enter and survive within host 
immune cells such as dentritic cells and macrophages (Reyes et al.,2013b). In 
the case of P. gingivalis, this pathogen has been shown to gain entry into 
dentritic cells and to disrupt their phagocytic function (Zeituni et al.,2009). In 
patients with chronic periodontal disease and severe cardiovascular disease P. 
gingivalis has been detected in circulating dendritic cells (Carrion et al.,2012). 
Therefore, although studies to date point to survival within host cells as a 
mechanism of dissemination for pathogens to atherosclerotic lesions, this theory 
remains unproven.  
 
P. gingivalis virulence factors and pathogenic mechanisms  
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The pathogenicity of P. gingivalis has been attributed to a panel of virulence 
factors which allow the bacterium to subvert innate immunity and colonize the 
host (Hajishengallis, 2009). Among the virulence factors expressed include 
modifications to the outer membrane component that interacts at TLR4 (lipid A), 
cysteine proteases (gingipains), adhesive hair-like appendages emanating from 
the bacterial cell surface (fimbriae) and a capsule (Figure 1). Virulence factors 
not only provide a means for bacterial colonization of the host, but also serve as 
a mechanism for evading host defenses. Pathogens which successfully 
undermine the host response appear to preferentially target innate immunity 
(Rosenberger and Finlay, 2003), partly because these are the defense 
mechanisms first encountered by pathogens (Hajishengallis, 2011). The 
expression of these factors in various P. gingivalis strains varies (Rodrigues et 
al.,2012). The basis for this variation in strain virulence currently remains 
unknown (Singh et al.,2011). Our laboratory strain P. gingivalis 381 utilizes the 
factors listed in Figure 1, except for expression of a capsule (Rodrigues et 
al.,2012).  
 
Expression of modified lipid A has been attributed to the ability of P. gingivalis to 
evade / antagonize host responses at TLR4 (Coats et al.,2007; 2009a; 2011) 
(Figure 1). P. gingivalis gingipain activity contributes to attenuated production of 
the cytokines IL-6 and IL-8  (Mikolajczyk-Pawlinska et al.,1998). Furthermore, 
gingipain activity has been shown to degrade receptor interacting protein kinases 
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(RIPK), which intercepts intracellular host cell signaling pathways (Madrigal et 
al.,2012). A number of studies have been performed assessing the role of P. 
gingivalis fimbriae on host cell invasion and bacterial survival (Lamont and 
Jenkinson, 1998; Wang et al.,2007) (Figure 1). Two types of P. gingivalis fimbrial 
structures have been described. These comprise the “major” fimbriae encoded 
by the fimA gene and the “minor” fimbriae encoded by the mfa1 gene (Pierce et 
al.,2009). The majority of reports on the virulence of P. gingivalis fimbriae have 
been on the “major” fimbriae (Pierce et al.,2009). Primarily through fimbriae 
mediated manipulation of complement receptor 3 (CR3) and TLR2 signaling, P. 
gingivalis suppresses levels of IL-12 to promote its intracellular survival 
(Hajishengallis et al.,2007; Wang et al.,2007). In regards to atherosclerosis, P. 
gingivalis fimbriae induce endothelial activation, and possibly dysfunction, 
through activation of innate immunity and inflammation (Rodrigues et al.,2012). 
In vivo, the Genco laboratory has demonstrated that only invasive bacteria, 
expressing major fimbriae, accelerate atherosclerosis (Gibson et al.,2004).  
 
Higher virulence potentials of encapsulated strains than of nonencapsulated 
ones have been evaluated using a mouse abscess model (Ebersole et al.,1995; 
Laine and van Winkelhoff, 1998) suggesting that the capsule plays a significant 
role in the virulence of the bacterium (Singh et al.,2011). In vitro studies have 
shown that the capsule of P. gingivalis plays an important role in evading 
activation of the host immune system, as determined by reduced production of 
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pro inflammatory cytokines (Brunner et al.,2010). In turn, dampened immunity 
promotes survival of the bacterium within host cells (Singh et al.,2011). Although 
our laboratory strain 381 is nonencapsulated, this strain is able to survive within 
host cells and accelerates atherosclerosis in vivo (Rodrigues et al.,2012).  
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Virulence Factor Description Mechanism References 
Modified Lipid A  Outer Membrane 
Component 
TLR4 Evasion 
TLR4 Antagonism 
(Coats et 
al.,2007; 2009a; 
2011) 
 
Gingipains Cyteine 
Proteases 
Cleavage of Host Proteins Mikolajczyk-
Pawlinska et 
al.,1998; Madrigal 
et al.,2012 
Fimbriae  Hair-like 
Appendages 
Emanating from 
Bacterial Surface 
Attachment and Invasion  
Intracellular Survival 
Lamont and 
Jenkinson, 1998; 
Hajishengallis et 
al.,2007; Wang et 
al.,2007     
Capsule  Polysaccharide 
Layer on Cell 
Envelope  
Dampened Inflammatory 
Mediators  
Bacterial Survival  
Increased Virulence in 
Animal Models  
Brunner et 
al.,2010; Singh et 
al.,2011; 
Ebersole et 
al.,1995; Laine 
and van 
Winkelhoff, 1998 
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Figure 1. P. gingivalis virulence factors that contribute to immune 
subversion. Expression of modified lipid A, gingipains and fimbriae contribute to 
the ability of P. gingivalis to colonize the host and dampen innate immunity. 
Modified lipid A promotes pathogen evasion and antagonism of TLR4-mediated 
host responses. Gingipain activity leads to cleavage of the cytokines IL-6 and IL-
8 and the intracellular signaling proteins, RIPKs. Expression of fimbriae promotes 
host cell invasion and intracellular bacterial survival. Finally, encapsulated strains 
of P. gingivalis have been shown to dampen production of inflammatory 
mediators from host cells which promotes bacterial survival and increased 
virulence in animal models.  
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In contrast to immune evasion, P. gingivalis strongly activates TLR2 through host 
detection of lipoprotein, fimbriae, and phosphorylated dihydroceramides (Davey 
et al.,2008; Nichols et al.,2012; Jain et al.,2013). Previous work from the Genco 
laboratory has demonstrated that P. gingivalis-induced oral inflammatory bone 
loss and acceleration of systemic inflammation is dependent on TLR2 signaling 
(Hayashi et al.,2010b; Papadopoulos et al.,2013). Therefore, it would appear that 
P. gingivalis does not induce overall immunosuppression, but rather exploits 
selective host signaling pathways, thereby eliciting nonproductive inflammation 
that contributes to damaging inflammation (Hajishengallis, 2009). For example, in 
the very early stages of infection, P. gingivalis may suppress host defenses in 
order to facilitate its colonization (Hajishengallis, 2009). At later stages of 
infection, P. gingivalis stimulation of inflammatory pathways may provide 
nutrients, such as hemin, which is an essential source of iron for this pathogen 
(Hajishengallis, 2009). Additionally, through fimbriae interactions with CR3, P. 
gingivalis inhibits IL-12 production, which would lead to its bacterial clearance, 
but concurrently promotes TNFα levels (Hajishengallis et al.,2007), which 
contributes to periodontal bone loss (Graves, 2008). These studies illustrate how 
P. gingivalis has evolved to establish chronic persistence: the ability of a 
pathogen to evade host immunity without inhibiting the overall inflammatory 
response (Hajishengallis, 2011). Understanding the mechanisms by which P. 
gingivalis evades innate immunity is essential to further understanding this 
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pathogen’s role in periodontitis and associated systemic diseases 
(Hajishengallis, 2009).  
 
Bacterial lipid A and evasion of TLR4 signaling   
A number of highly successful Gram-negative organisms have evolved 
mechanisms to modify their lipid A species, the component of bacterial LPS that 
directly activates the TLR4 complex, as a strategy to evade immune detection 
and establish infection (Miller et al.,2005). Typically, host recognition of Gram-
negative bacteria occurs via detection of lipid A expressed on the bacterial 
membrane by the innate immune receptor, TLR4 (Akira et al.,2001). This initial 
recognition is critical for instructing host immunity and promoting an inflammatory 
response that eradicates the pathogen from the host (Akira et al.,2001; Munford 
and Varley, 2006). However, modifications to lipid A structure leads to dampened 
host immunity and pathogen persistence (Needham and Trent, 2013).  
 
Lipid A is initially synthesized as a β-1’,6-linked disaccharide of glucosamine that 
is di-phosphorylated and hexa-acylated (Needham and Trent, 2013). An 
unmodified version of this lipid A structure is typically expressed by enteric 
bacteria, such as Escherichia coli and induces a robust inflammatory response 
(Raetz and Whitfield, 2002). Modifications to this basic lipid A structure are 
observed in alterations to acyl chains or terminal phosphate groups (Coats et 
al.,2011). Studies have shown that modification of the lipid A moiety to a less 
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acylated form facilitates bacterial evasion of host innate immunity, thereby 
enhancing pathogenicity (Matsuura et al.,2012). A decrease in one acyl group 
(from six to five) is enough for Salmonella to evade innate immunity (Matsuura et 
al.,2012). Furthermore, H. pylori (Cullen et al.,2011), Legionella pneumophila 
(Neumeister et al.,1998), Yersinia pestis (Kawahara et al.,2002), and Francisella 
novicida (Hajjar et al.,2006) express underacylated lipid A moieties, in 
comparison to the canonical LPS expressed by E. coli, and are poorly recognized 
by TLR4.  
 
Expression of divergent lipid A structures has shown to be highly regulated by 
local environmental conditions. Y. pestis (Rebeil et al.,2006) and Francisella 
tularensis (Li et al.,2012) expression of structurally divergent forms of lipid A is 
highly regulated by temperature, allowing these pathogens to adapt to harsh 
environmental conditions in the host. The major lipid A component expressed by 
Y. pestis is lipid IVA, which is a tetra-acylated structure and an intermediate in 
the biosynthetic pathway of lipid A (Montminy et al.,2006). Expression of this 
tetra-acylated form is believed to allow Y. pestis to proliferate undetected in the 
bloodstream during early stages of infection (Needham and Trent, 2013). 
Utilization of a genetically-modified Y. pestis, which expresses an 
immunostimulatory version of LPS, results in reduced microbial survival in the 
host (Montminy et al.,2006). Therefore, the ability of Gram-negative pathogens to 
cause persistent infection and severe disease is partially due to evasion of host 
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immune detection at TLR4 through modification of lipid A moieties (Maeshima 
and Fernandez, 2013).  
 
Likewise, P. gingivalis weakly activates TLR4 through expression of a 
heterogeneous LPS that contains lipid A structures that vary in the number of 
phosphate groups and the amount and position of lipid A fatty acids (Kumada et 
al.,1995; Bainbridge et al.,2002). P. gingivalis expresses underacylated lipid A 
structures that can be penta-acylated forms, conferring TLR4 agonistic activity, or 
tetra-acylated forms, functioning as TLR4 antagonists, or are non-activating 
(Coats et al.,2005; Reife et al.,2006). These structures typically express mono- or 
di-phosphate terminal groups. Expression of divergent structural moieties by P. 
gingivalis changes depending on growth phase, temperature, and levels of hemin 
(Al-Qutub et al.,2006; Coats et al.,2009a; Curtis et al.,2011).  Recently, it has 
been demonstrated that P. gingivalis also expresses a unique non-
phosphorylated, tetra-acylated lipid A that is regulated by levels of hemin (Coats 
et al.,2009a). During hemin-deplete conditions, P. gingivalis utilizes endogenous 
lipid A 1- and 4’-phosphatase activities to express a non-phosphorylated, tetra-
acylated lipid A that is immunologically inert at the TLR4 complex, as well as a 
mono-phosphorylated, penta-acylated lipid A that functions as a weak TLR4 
agonist (Al-Qutub et al.,2006; Rangarajan et al.,2008; Coats et al.,2009a). Under 
hemin-replete conditions, the activity of 1-phosphatase is suppressed, resulting 
in the expression of a mono-phosphorylated, tetra-acylated lipid A species that 
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functions as TLR4 antagonists (Coats et al.,2009a). Expression of these different 
structural types is believed to allow P. gingivalis to evade immune detection at 
TLR4 (Herath et al.,2013). 
 
Bacterial lipid A and evasion of inflammasome activation   
Recently, it has been revealed that in addition to evasion of TLR4 signaling, lipid 
A modifications result in attenuated activation of the inflammasome (Kayagaki et 
al.,2011; Rathinam et al.,2012; Broz and Monack, 2013; Hagar and Miao, 2014; 
Shi et al.,2014). The inflammasome is a multi protein complex that upon 
activation cleaves caspase-1 to its mature and active form (Davis et al.,2011). 
Active caspase-1 subsequently cleaves the pro form of the inflammatory 
cytokines IL-1β and IL-18 to their mature and active forms (Figure 2), cytokines 
that are necessary during pathogenic infection (Taxman et al.,2010).  Active 
caspase-1 is also associated with an inflammatory cell death, termed pyroptosis, 
which facilitates the release of the pro inflammatory cytokine IL-1α (Mariathasan 
and Monack, 2007) (Figure 2).  
 
Activators of the inflammasome can be divided into two separate categories: 
sterile and foreign (Davis et al.,2011).  Sterile activators can be either self-
derived, such as adenosine triphosphate (ATP) and cholesterol crystals, or 
environmentally derived, such as Alum and ultraviolet (UV) radiation (Davis et 
al.,2011). The inflammasome is thought to sense the mislocalization of these 
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endogenous molecules. For example, ATP is normally localized to the cytosol; 
however, once recognized in the extracellular environment, an inflammatory 
response ensues (Xiang et al.,2013). Foreign activators of the inflammasome 
include virulence factors that that are expressed by invading pathogens. These 
include bacterial pore-forming toxins or flagellin, viral RNA or fungus-derived β-
glucans and zymosan (Davis et al.,2011).   
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Figure 2. Model for canonical and non-cononical inflammasome signaling. 
The canonical inflammasome requires a two-step activation process. The first, 
results from PRR stimulation from PAMPs such as bacterial LPS. A second 
signal arises from danger signals that are either sterile or pathogen derived, such 
as ATP. These signals result in activation of the inflammasome complex and 
subsequent cleavage of pro caspase-1 to its mature and active form. 
Downstream events associated with inflammasome activation include the 
inflammatory cell death pyroptosis and release of the inflammatory mediators IL-
1β, IL-1α and IL-18. A novel non-canonical inflammasome, relying on caspase-
11, has been shown to be activated during Gram-negative bacterial infections. It 
was originally proposed that an unknown sensor in the cytosol detected Gram-
negative bacterial lipid A, however it is now thought that caspase-11 may detect 
lipid A directly, leading to subsequent caspase-1 activation and IL-1β and IL-18 
release. Caspase-11 activation results in pyroptosis and IL-1α release, 
independent of caspase-1 activation.  
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Recently, a novel non-canonical inflammasome was discovered that relies on 
activation of an additional caspase, caspase-11 (Kayagaki et al.,2011; Broz et 
al.,2012; Rathinam et al.,2012) (Figure 2). Caspase-11 functions upstream of 
caspase-1, therefore upon activation, caspase-11 functions to cleave caspase-1 
resulting in cytokine maturation and release of IL-1β and IL-18 (Broz and 
Monack, 2013). Furthermore, activation of caspase-11 results in pyroptosis and 
IL-1α release that is independent of caspase-1 activation (Kayagaki et al.,2011) 
(Figure 2). Activation of the non-canonical inflammasome was initially observed 
in response to a number of Gram-negative bacteria, but not with Gram-positive 
bacteria (Rathinam et al.,2012). This distinction, lead to the discovery that 
bacterial lipid A is responsible for activating caspase-11 (Kayagaki et al.,2013).  
Originally, it was proposed that there was an unknown sensor in the cytosol that 
recognized lipid A (Kayagaki et al.,2013), however, it is now believed that 
caspase-11 itself might be capable of directly sensing lipid A (Shi et al.,2014).  
 
Like evasion of TLR4 signaling, Gram-negative pathogens have evolved 
mechanisms to evade caspase-11 detection. Pathogens that express 
underacylated structures do not activate the non-canonical inflammasome, while 
pathogens expressing the canonical hexa-acylated lipid A induce a robust 
inflammasome response. For example, H. pylori, through expression of a tetra-
acylated lipid A, has successfully adapted to evade activation of the 
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inflammasome, while pathogens such as E. coli, expressing the canonical hexa-
acylated lipid A, activate the inflammasome (Kayagaki et al.,2013).  
 
Due to its role in host innate defense, it is not surprising that pathogens have 
evolved mechanisms to evade activation of the inflammasome (Taxman et 
al.,2010). Upon activation, production of IL-1β serves as an “alarm” to infection, 
resulting in the expression of adhesion molecules that promote leukocyte 
infiltration from the blood into tissues (Sims and Smith, 2010). Additionally, 
activation of the inflammasome results in cell lysis, due to activation of pyroptosis 
(Lamkanfi, 2011). Therefore, pyroptosis not only serves to alert the host of the 
infection but also removes a pathogen’s intracellular niche (Shimada et al.,2012). 
Due to these downstream events following inflammasome activation, pathogen 
evasion of inflammasome activation has been proposed to serve a dual role: to 
dampen cytokine production and to prevent host cell death in order to provide an 
intracellular niche for the pathogen to survive (Shimada et al.,2012; Cemma and 
Brumell, 2013).  
 
Autophagy  
Another mechanism utilized by pathogens for intracellular survival involves 
manipulation of the autophagic pathway (Deretic and Levine, 2009; Levine et 
al.,2011; Cemma and Brumell, 2013; Choy and Roy, 2013; Huang and Brumell, 
2014). Autophagy is a cell autonomous, host quality control pathway required to 
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maintain cellular homeostasis. The term autophagy encompasses a collection of 
diverse processes that share a common purpose of digesting cellular cytoplasmic 
contents within lysosomes (Deretic et al.,2013). Different forms of autophagy 
include macroautophagy, microautophagy, chaperone mediated autophagy 
(Mizushima et al.,2011) and non-canonical autophagy (Codogno et al.,2012). 
The activation of these different pathways provides specificity in the autophagic 
response. On one hand, autophagy can function as a delicate process by directly 
importing individual cytosolic proteins, containing specific recognition motif 
sequences, into the lysosome (chaperone-mediated) (Deretic and Levine, 2009). 
On the other hand, autophagy can act as a bulk process, capturing large portions 
of the cytosol or big organelles, such as mitochondria (macroautophagy) (Deretic 
and Levine, 2009).  
 
Activation of autophagy relies on a complex of evolutionarily conserved gene 
productions, known as the Atg proteins, which prompt the formation of short-lived 
membrane crescents in the cytoplasm termed phagophores, or isolation 
membranes, which sequester cytoplasmic material (Deretic and Levine, 2009; 
Mizushima et al.,2011; Choy and Roy, 2013) (Figure 3). These phagophores 
subsequently progress into double membrane vesicles called autophagosomes, 
which are considered the principal morphological feature of autophagy (Choy and 
Roy, 2013; Deretic et al.,2013) (Figure 3).  Autophagosomes mature into single-
membrane autolysosomes upon fusion with lysosomal organelles resulting in the 
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degradation of intracellular contents (Deretic and Levine, 2009) (Figure 3). 
Autophagy plays a critical role in cell survival by recycling cellular components 
during periods of limited nutrients; therefore, a basal level of autophagy occurs in 
almost every cell type (Yorimitsu and Klionsky, 2005; He and Klionsky, 2009). 
The metabolic aspects of autophagy are under negative control by growth factors 
such as type I phosphatidylinositol 3 kinase (PI3K) (Deretic and Levine, 2009). 
The mammalian target of rapamycin (mTOR) serves as a master metabolic 
regulator for autophagy induction by sensing growth factors, nutrient signals and 
energy status (Into et al.,2012; Deretic et al.,2013). In response to growth factors 
and nutrient-rich conditions, mTOR inhibits autophagy (Sanjuan et al.,2009) while 
under nutrient deprived conditions (starvation), mTOR is inhibited leading to 
autophagy activation (Deretic et al.,2013).  
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Figure 3. The process of autophagy. Activation of autophagy results in a 
portion of the cytoplasm sequestered within a phagophore, also known as an 
isolation membrane. The phagophore progresses to form a double membrane 
vesicle termed the autophagosome. The autophagosome subsequently fuses 
with the lysosome and the internal material is degraded in an autolysosome. Key 
proteins of the autophagy pathway include the adapter protein p62, the 
autophagosome membrane protein LC3-II and the lysosomal protein LAMP-1.  
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Autophagic mechanisms for clearance of intracellular pathogens 
A rapidly developing area of autophagy research involves investigating the 
immunological functions of this pathway (Deretic and Levine, 2009; Levine et 
al.,2011). Although classically appreciated for its role in cellular homeostasis, 
autophagy is now recognized to play an important role in innate defense against 
a number of intracellular pathogens (Choy and Roy, 2013). The process of 
autophagy functioning as a cell-autonomous defense by eliminating intracellular 
pathogens within double membrane autophagosomes has been termed 
xenophagy (Levine, 2005). The precise membrane dynamics and specific 
determinants of xenophagy are not fully understood (Levine et al.,2011). 
However, some pathogens that have been identified to be eliminated by 
xenophagy include, Salmonella Typhimurium (Birmingham et al.,2006), Listeria 
monocytogenes (Py et al.), F. tularensis (Checroun et al.,2006), Group A 
Streptococcus (Nakagawa, 2004) and Mycobacterium tuberculosis (Rich et 
al.,2003).  
 
Although the end result of xenophagy is pathogen degradation by 
autolysosomes, the mechanism for clearance is complex, and often times is not 
mutually exclusive for all pathogens (Extensively reviewed by (Deretic and 
Levine, 2009) Figure 4). Upon invasion of host cells, bacteria reside in 
bacterium-containing vacuoles or phagosomes, which can be directly trafficked to 
autophagosomes for degradation (Figure 4).  For example, Mycobacterium 
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tuberculosis resides within intact phagosomes in murine macrophages and 
becomes targeted to the autophagic pathway (Gutierrez et al.,2004; Collins et 
al.,2009). Other bacterial species damage the vacuolar membrane (Figure 4) as 
is the case with S. Typhimurium, as determined by co-localization to the 
autophagy protein microtubule-associated protein light chain 3 (known as LC3 II, 
a mammalian homolog of yeast Atg8) to vacuolar markers (Birmingham et 
al.,2006). Damage to the vacuolar membrane can result in pathogen release into 
the cytosol (Figure 4), which has been observed with Group A streptococcus 
(Nakagawa, 2004). Damaged vacuolar components or cytosolic bacteria are 
targeted for degradation by the autophagy pathway in an ubiquitin-dependent 
manner (Cemma and Brumell, 2012).  Ubiquinitated cargo becomes trafficked to 
autophagosomes by adaptor proteins that recognize both ubiquitin (Geetha and 
Wooten, 2002) and LC3 expressed on autophagosomes (Komatsu et al.,2007; 
Pankiv et al.,2007) (Figure 4). Essentially, adaptor proteins serve as the 
functional link between ubiquintiated microorganisms and autophagosomes. The 
host protein p62 plays an important role in recognizing ubiquitinated substrates 
for autophagy and has been shown to play a role in trafficking intracellular 
bacteria, such as Listeria and Salmonella, to autophagosomes (Yoshikawa et 
al.,2009; Zheng et al.,2009).   
 
A fairly new and noncanonical pathway for targeting microorganisms to 
autophagosomes has been indentified. This pathway has been primarily 
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identified in macrophages, and is termed “LC3 associated phagocytosis” or LAP 
(Sanjuan et al.,2009; Mehta et al.,2014) (Figure 4). LAP involves the direct 
recruitment of LC3 to bacteria containing phagocytic vesicles upon TLR ligation, 
resulting in rapid and direct transport of bacteria to lysosomes (Sanjuan et 
al.,2007; Henault et al.,2012) (Figure 4). Initial observations of this pathway were 
seen with Saccharomyces cerevisiae and E. coli infection, where shortly after 
internalization LC3 was found bound to phagosomes (Sanjuan et al.,2007) 
(Figure 4). This finding was further investigated by the use of particles coated 
with zymosan. Engulfed particles were rapidly decorated with LC3 upon ingestion 
(Sanjuan et al.,2009). Interestingly, macrophages deficient in TLR2 were 
inefficient in inducing the translocation of LC3 to the phagosome, suggesting that 
engagement of TLRs is an essential step for induction of this pathway (Sanjuan 
et al.,2007). Interestingly, LAP is independent of the autophagy protein ULK1, a 
serine/threonine protein kinase that is needed to generate autophagosomes 
during times of starvation (Deretic et al.,2013). Therefore, identification of 
autophagosomes, which are typically associated with canonical autophagy 
induction, are absent with LAP induction.  
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Figure 4. Autophagy dependent mechanisms for bacterial degradation. 
After initial invasion of host cells, bacteria reside in a phagosome or a “bacteria-
containing vacuole”. Some bacteria damage these vacuolar compartments in 
order to escape into the cytosol. These damaged vacuolar compartments or 
cytosolic bacteria can be ubiquinated and subsequently trafficked to 
autophagosomes by the adaptor protein, p62. Fusion of autophagosomes with 
lysosomes results in the formation of an autolysosome and degradation of the 
intracellular contents. Another recently discovered mechanism for trafficking of 
pathogens to autophagosomes, is LC3 associated phagocytosis (LAP). In this 
mechanism, TLR ligation triggers direct recruitment of the autophagy protein LC3 
to the phagosome. This pathway is independent of the classical double 
membrane autophagosomes, thereby allowing for the direct trafficking of 
pathogens to the lysosome and rapid degradation of invading bacteria.   
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Role of TLRs in autophagy activation  
It is now well recognized that the ancient defense mechanism of autophagy has 
been well integrated with other immune-sensing systems, such as those 
controlled by pattern recognition receptors. Autophagy is both a regulator and an 
effector of pattern recognition receptor responses to pathogens (Deretic, 2012b; 
Into et al.,2012) In recent years, a number of studies have pointed to a link 
between TLR stimulation and autophagy activation (Xu et al.,2007; Delgado et 
al.,2008; Shi and Kehrl, 2008).  
 
TLR ligation increases the number of double membrane LC3-positive organelles 
inside the cell after several hours of stimulation (Xu et al.,2007; Delgado et 
al.,2008). Enhancement of autophagy using TLR ligands has been shown to 
reduce the replication capabilities of cytoplasmic pathogens (Sanjuan et 
al.,2009). As mentioned previously, a noncanonical form of autophagy is 
activated when TLR2 recognizes zymosal during phagocytosis of fungi, leading 
to the recruitment of the autophagy proteins Atg5, Atg7 and LC3 to the 
phagosome (Sanjuan et al.,2007). A recent report indicated that TLR2-activated 
ERK is important for the induction of autophagy and elimination of L. 
monocytogenes (Into et al.,2012). Engagement of TLR4 or TLR7 is linked to 
efficient clearance of phagocytosed Mycobacterium (Into et al.,2012). 
Furthermore, TLR4 recognition of LPS has shown to lead to selective clearance 
of Salmonella and Shigella (Into et al.,2012). These reports present compelling 
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evidence for the role of PAMPs in activating autophagy pathways for the 
elimination of invading microorganisms (Sanjuan et al.,2007; Delgado et al.,2008; 
Yano et al.,2008). The signal transduction pathways between agonist-stimulated 
receptors and autophagy activation remain to be fully delineated (Sanjuan et 
al.,2009; Mehta et al.,2014). Therefore, the role of TLRs in modulation of 
autophagy is currently an important area of research.  
 
There are discrepancies in our current knowledge on how TLRs modulate 
autophagy activation, which is primarily due to reports on adaptor usage 
downstream of TLR activation. The major TLR signaling pathways are initiated 
via two key adaptor proteins, Myd88 (Myeloid differentiation factor 88) and TRIF 
(Watters et al.,2007; Kawai and Akira, 2010). MyD88 is employed by all TLRs, 
except TLR3, and mediates initiation of the signaling pathways for activation of 
the transcriptional factor NF-κB (Nuclear Factor κB) and the cascades of 
mitogen-activated protein kinases (MAPKs). TRIF is only used by TLR3 and 
TLR4 and activates both pathways for NFκB and the transcriptional factor 
Interferon regulatory factor 3 (IRF3) (Into et al.,2012).  
 
Xu et al. in 2007 were the first to report that TLR4 stimulation activates 
autophagy and enhances the autophagic elimination of phagocytosed 
mycobacteria in macrophages (Xu et al.,2007). In this study, TLR4 induced 
autophagy was dependent on TRIF but did not require MyD88 participation. In a 
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different study, it was reported that MyD88 was required for TLR7-mediated 
autophagy induction (Delgado et al.,2008). In an additional study by Shi et al (Shi 
and Kehrl, 2008) it was revealed that TLR-activated autophagy is regulated by 
the interaction of MyD88 or TRIF with the autophagy protein Beclin-1. Therefore, 
although there appears to be a role of TLRs in autophagy induction, our 
understanding of the signal transduction pathways leading to autophagy 
activation has remained limited (Into et al.,2012).  
 
Pathogen evasion of autophagy 
A number of highly evolved pathogens have developed strategies to avoid 
autophagic degradation in order to survive and establish persistent infection 
(Colombo, 2005; Ogawa et al.,2005; Moreau et al.,2010; Yuk et al.,2012; Choy 
and Roy, 2013; Kirkegaard et al.). Just as there are multiple strategies used by 
the host autophagic machinery to eliminate invading microbes (Figure 4), there 
are a number of microbial adaptations to counteract these mechanisms (Figure 
5) (Ray et al.,2009; Thi et al.,2012). Evasion of autophagy appears to be 
pathogen specific and can include either prevention of autophagy induction, 
avoidance of pathogen recognition or prevention of autophagosome / lysosome 
maturation (Deretic and Levine, 2009; Levine et al.,2011) .  
 
Intracellular bacterial pathogens that utilize the cytoplasm for replication escape 
from membrane-bound phagosomes (Price and Vance, 2014) (Figure 5A). Once 
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in the cytosol, expression of surface proteins mask bacterial pathogens from 
autophagic recognition and subsequent degradation in lysosomes (Cemma and 
Brumell, 2012). This phenomenon has been observed for a number of pathogens 
including – S. flexneria, L. monocytogenes, F. tularenis and Burkholderia 
pseudomallei (Deretic and Levine, 2009; Price and Vance, 2014). Interestingly, 
for L. monocytogenes although the majority of the bacteria successfully evade 
autophagy in the cytosol, a subpopulation has been observed in single-
membrane vesicles associated with LAP (Birmingham et al.,2007). These 
compartments are non-degradative due to the ability of this pathogen to block the 
maturation of phagosomes to lysosomes (Figure 5E). These studies with L. 
monocytogenes provide an example of how multiple independent mechanisms 
can result in pathogen evasion of autophagy, suggesting that the autophagy-
bacteria interaction is a constantly evolving arms race (Choy and Roy, 2013).  
 
In contrast to cytosolic bacteria, there are those that are confined to a variety of 
membrane-bound compartments, which are typically derived from the 
phagosome and are referred to as the “bacteria-containing vacuole” (Price and 
Vance, 2014) (Figure 5B). Although these bacteria-containing vacuoles obtain 
autophagic markers, they do not fuse with the lysosome. This creates a non- 
acidic replicative niche for bacterial survival (Figure 5C). Such pathogens that 
block autophagosome progression include S. aureus (Fang et al.,2014), 
Anaplasma phagocytophilium (Niu et al.,2008) and Y. pseudotuberculosis 
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(Moreau et al.,2010). Other pathogens, such as L. pneumophila delay autophagic 
maturation in order to differentiate into an acid-tolerant form, which allows the 
pathogen to survive in an acidic environment once autophagosomes fuse with 
lyososmes (Amer and Swanson, 2005) (Figure 5D).   
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Figure 5. Bacterial targeting of the autophagic pathway for survival. A 
number of pathogens have adapted to escape from the phagosome in order to 
gain intracellular motility and to replicate in the cytosol (A). Other bacterial 
pathogens remain confined within bacteria-containing vacuoles (B). These 
vacuoles contain autophagic markers, but do not progress to lysosomal fusion, 
which provides a non-acidic replicative niche for pathogens to survive (C). In 
addition to blocking autophagosome / lysosomal fusion, pathogens also delay 
this event in order to differentiate into an acid-resistant form that allows bacterial 
replication in an acidic autophagolysosome (D). Finally, some bacterial species 
that are targeted by LAP can block lysosome fusion to the LC3 positive 
phagosome (E).  
 
  
 
41 
The virulence factors pathogens utilize to manipulate the autophagic pathway are 
highly varied and remain to be clearly defined. Research thus far has indicated 
that bacteria secretion of virulence-associated proteins, either effectors or toxins, 
modulate autophagy during infection (Cemma and Brumell, 2012). Notably, the 
pathogens Brucella abortus and L. pneumophila are very close relatives and both 
utilize a type IV secretion system to gain entry into autophagosomes (Amer and 
Swanson, 2005; Starr et al.,2012).  Expression of a type III secretion system by 
Shigella has been shown to contribute to the ability of this pathogen to evade 
elimination by autophagy (Ogawa et al.,2005; Ogawa and Sasakawa, 2006). 
Understanding which virulence factors contribute to the ability of pathogens to 
gain access to autophagic vacuoles has been of great interest because 
identification of these factors may provide additional strategies for therapeutic 
intervention in infectious diseases (Yuk et al.,2012).  
 
Much of our knowledge on how pathogens interact with the autophagic pathway 
has resulted from in vitro studies. Whether these mechanisms are important in 
microbial pathogenesis in vivo remains to be explored (Deretic and Levine, 
2009). There have been a few in vivo studies that point to a protective role for 
autophagy against infection. For example, by utilizing a mouse model for 
autophagy, with a specific deletion of the autophagy protein Atg5 in the myeloid 
lineage, Zhao et al demonstrated that Atg5 is key in controlling T. gondii infection 
in vivo (Zhao et al.,2007). Furthermore, utilizing this same mouse model Castillo 
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et al.were able to demonstrate that autophagy plays a dual role against 
tuberculosis in vivo by suppressing both M. tuberculosis growth and damaging 
inflammation (Castillo et al.,2012).  
 
Additional roles for autophagy in immunity 
In addition to its role in eliminating microorganisms, autophagy plays a role in 
immunity by controlling inflammation and secretion of immune mediators (Deretic 
et al.,2013). Autophagy functions to prevent basal levels of inflammasome 
activation by targeting components of the inflammasome complex for autophagic 
degradation (Nakahira et al.,2011; Zhou et al.,2011; Shi et al.,2012). Several 
studies have reported on the regulatory action of autophagic machinery on 
inflammasome activity (Vural and Kehrl, 2014). In Atg16L1 deficient 
macrophages, elevated levels of IL-1β and caspase-1 were observed suggesting 
that in the absence of autophagosomes, there is a significant reduction of 
autophagy dependent degradation of inflammasome-associated proteins (Saitoh 
et al.,2008). In a study by Harris et al.,it was shown that IL-1β is directly targeted 
for degradation by autophagosomes (Harris et al.,2011). Furthermore, Shi et 
al.demonstrated that activation of the inflammasome led to the formation of 
autophagosomes, suggesting that autophagy functions to limit inflammasome 
activity by engulfing and degrading inflammasome components (Shi et al.,2012).  
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In contrast to preventing inflammasome activation, autophagy has been shown to 
play a role in the extracellular release of the mature form of IL-1β (Dupont et 
al.,2011).  Since IL-1β is a cleaved protein, it lacks the pro-peptide sequence 
required for conventional secretion through the endoplasmic reticulum. 
Therefore, it is has been proposed that an unconventional secretory pathway is 
likely responsible for the extracellular release of IL-1β (Dubyak, 2012). Dupont et 
al.recently reported that cytosolic IL-1β is captured and released in 
autophagosomes, demonstrating for the first time that inflammasome and 
autophagy pathways synergize during IL-1β secretion (Dupont et al.,2011). 
Importantly, this result only occurred when cells were undergoing active 
autophagy.  
 
Collectively, studies to date point to a dual role for autophagy in regulating 
inflammasome activity. Basal autophagy functions to inhibit unwarranted 
inflammasome activation and IL-1β secretion (Nakahira et al.,2011; Zhou et 
al.,2011), while induced autophagy functions to facilitate the unconventional 
secretion of IL-1β (Dupont et al.,2011). This finding has been important in the 
context of understanding and designing therapeutics for inflammatory diseases. 
We now know perturbations in autophagy-protein dependent functions in 
immunity may not only lead to an increased susceptibility to infection, but also to 
chronic inflammatory diseases and autoimmune diseases (Levine et al.,2011). To 
date, the only well-characterized example of this has been shown for Crohn’s 
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disease, where mutations in autophagy regulators leads to exacerbated 
inflammation and disease (Levine et al.,2011).  
 
P. gingivalis survival within host cells   
Included in the list of pathogens that have been reported to use autophagic 
machinery for survival is P. gingivalis. To date, there is limited knowledge on how 
P. gingivalis infiltrates the autophagic pathway for intracellular survival. Although 
the bacterial determinants and precise details that contribute to P. gingivalis 
trafficking to autophagosomes remain to be defined (Deretic and Levine, 2009), it 
is likely that it is cell type specific. In human coronary artery endothelial cells 
(HCAEC), P. gingivalis has been reported to utilize a specific lipoprotein (gene 
PG0717) to traffic to autophagosomes (Reyes et al.,2013a). Deletion of PG0717 
resulted in an impaired ability of P. gingivalis to usurp the autophagic pathway in 
HCAEC. In human myeloid dentritic cells P. gingivalis has been shown to use its 
minor fimbriae to engage DC-SIGN to evade autophagic clearance (Carrion et 
al.,2012). In murine macrophages, P. gingivalis has been shown to manipulate its 
interactions at TLR2 for bacterial survival (Wang et al.,2007). Also in murine 
macrophages, P. gingivalis has been shown to utilize its major fimbriae to 
promote internalization into lipid rafts for bacterial survival (Wang and 
Hajishengallis, 2008). It is thought that the lipid-raft route of microbial uptake 
affords protection from the intracellular degradative lysosomal pathway (reviewed 
by (Mañes et al.,2003)). This is attributed to the notion that internalized rafts do 
  
 
45 
not readily fuse with late endosomes and lysosomes (Simons and Gruenberg, 
2000). The trafficking of P. gingivalis containing lipid rafts is unknown, however 
other pathogens that hijack lipid rafts have been shown to infiltrate 
autophagosomes (Amer and Swanson, 2005). Which of these host cell signaling 
pathways and bacterial virulence factors that contribute to the ability of P. 
gingivalis to traffic to autophagosomes for intracellular survival in the 
macrophage remain elusive.  
 
The macrophage paradox 
For many diseases, pathogen survival and replication within macrophages 
represents an important step in early stages of infection for evading the immune 
response and enabling bacterial dissemination (Pujol and Bliska, 2005; Moreau 
et al.,2010). However, the extent to which infected macrophages circulate among 
tissues is not well established (Price and Vance, 2014). The possibility of P. 
gingivalis surviving within macrophages is intriguing in the context of the 
periodontitis-atherosclerosis connection (Lamont and Jenkinson, 1998). In the 
case of periodontitis, macrophages represent a primary cell population in chronic 
periodontal lesions (Hayashi et al.,2010a). Recently, it has been demonstrated 
that P. gingivalis induces infiltration of macrophages into the gingival tissue. 
Notably, macrophage depletion reduced P. gingivalis infection and alveolar bone 
loss (Lam et al.,2014). Macrophages also play an active role in atherosclerotic 
plaque initiation and formation through the initial accumulation of cholesterol in 
  
 
46 
the arterial wall (Cole et al.,2010a). P. gingivalis has been documented to 
contribute to this response by enhancing foam cell formation of macrophages 
when cultured in the presence of human LDL (Qi et al.,2003). Therefore due to 
the predominate role of macrophages in both diseases, it is conceivable that P. 
gingivalis survival within macrophages could promote relocation of this bacterium 
to systemic sites (Hajishengallis, 2009), such as atherosclerotic plaque, resulting 
in subsequent infection of cells comprising the lesion.  
 
The idea that pathogens may localize to macrophages as a mechanism for 
spread to systemic sites within the host proposes a very interesting question of 
why bacterial pathogens would “choose” to survive within a cell that has been 
equipped with killing mechanisms to destroy them (Price and Vance, 2014). This 
question has been termed the “macrophage paradox.” Macrophage microbial 
defenses include production of antimicrobial peptides (Nizet, 2006), reactive 
oxygen species (Nathan and Cunningham-Bussel, 2013) and as discussed 
above, autophagy.  Macrophages are also able to produce a number of pro 
inflammatory mediators, including cytokines and chemokines, which limit 
pathogen replication by recruiting other immune cells to the site of infection 
(Price and Vance, 2014).  As mentioned previously, part of this inflammatory 
response includes activation of the inflammasome and execution of a rapid form 
of cell death termed, pyroptosis (Miao et al.,2010). Activation of the 
inflammasome not only removes the intracellular niche for pathogen survival but 
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also results in the release of the critical proinflammatory cytokine, IL-1β (Taxman 
et al.,2010).  
 
It is possible that pathogens may not “elect” to localize to macrophages, but 
instead have no “choice” in the matter since it is most likely inevitable that a 
pathogen would find itself in a macrophage. It has been proposed by Vance et 
al.that bacterial localization to macrophages is actually a “strategic choice” (Price 
and Vance, 2014). Consequently, pathogens have likely evolved mechanisms in 
order to evade these host defenses in order to promote their adaptive fitness 
(Price and Vance, 2014). There are likely many, non-exclusive reasons for why 
pathogens would favor a macrophage niche and they are likely not the same for 
all pathogens. Understanding these pathogenic strategies for host cell survival 
will be critical in developing therapies for diseases plagued by persistent infection 
and chronic inflammation.  
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Hypothesis and Specific Aims  
The overall goal is to define the mechanisms by which P. gingivalis evades TLR4 
signaling and manipulates autophagy to promote chronic inflammation. P. 
gingivalis expresses a number of outer membrane components that bind to and 
signal through TLR2 and TLR4 (Hajishengallis, 2011). Importantly, P. gingivalis 
has evolved mechanisms to evade TLR4 host immune detection through 
expression of a heterogeneous lipid A species that functions as weak TLR4 
agonist, TLR4 antagonist or non-activating at TLR4 (Kumada et al.,1995; Al-
Qutub et al.,2006; Coats et al.,2009a). In contrast to evasion of TLR4 signaling, 
in vitro studies have documented that P. gingivalis is a strong activator of TLR2. 
P. gingivalis utilizes a TLR2-mediated mechanism for intracellular entry into 
macrophages, which protects the organism from immune clearance via the 
intracellular degradative lysosomal pathway (Wang et al.,2007; Wang and 
Hajishengallis, 2008). A number of successful intracellular pathogens evade 
lysosomal destruction via infiltration of the autophagic pathway (Yuk et al.,2012; 
Cemma and Brumell, 2013; Choy and Roy, 2013; Huang and Brumell, 2014). 
Autophagy is also utilized for the secretion of the active form of IL-1β, a mediator 
of bacterial killing (Taxman et al.,2010; Dupont et al.,2011). Whether P. gingivalis 
manipulates the autophagic pathway for survival is not known, although studies 
have demonstrated that in TLR2 deficient macrophages, P. gingivalis is rapidly 
killed (Wang et al.,2007). Based on these observations we hypothesize that the 
ability of P. gingivalis to evade TLR4 signaling and to manipulate autophagy 
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dampens IL-1β production and promotes survival in macrophages, resulting in 
chronic inflammation (Figure 6).  
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Figure 6. P. gingivalis exploitation of host innate immune defenses in the 
macrophage and induction of chronic inflammation. P. gingivalis engages 
TLR2 signaling and evades TLR4 signaling via expression of a modified lipid A 
species that function as a TLR4 agonist, TLR4 antagonist or non-activating at 
TLR4.  We propose that P. gingivalis 381 exploits host innate immunity by 
signaling through TLR2 and evading TLR4 signaling. TLR2 has been shown to 
facilitate lipid raft entry into macrophages. Pathogens that enter macrophages via 
lipid rafts have been shown to fuse intracellularly with autophagosomes, thereby 
providing an intracellular niche for the bacterium to survive. Infiltration of the 
autophagic pathway by P. gingivalis may obstruct IL-1β secretion, a 
proinflammatory cytokine that has been shown to be secreted in 
autophagosomes. We have shown that stimulation of macrophages using a 
genetically modified strain of P. gingivalis that is locked as a TLR4 agonist 
(PG1587381) induces an IL-1β response that is significantly greater than wild-type 
381 and is subjected to bacterial killing in the macrophage. We propose 
increased immunostimulatory potential at TLR4 activates autophagy, which 
facilitates IL-1β secretion and bacterial clearance. These events increase 
bacterial detection by the host resulting in decreased chronic inflammation at 
sites distant from infection.  
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Chapter 2. Materials and Methods  
Ethics Statement  
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health. The protocol was approved by Boston University’s Institutional Animal 
Care and Use Committee (IACUC) protocol numbers AN15312 and AN14348. 
Boston University is committed to observing federal policies and regulations and 
Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) International standards and guidelines for humane care and use of 
animals. Federal guidelines, the Animal Welfare Act (AWA) and The Guide were 
followed when carrying out experiments. Procedures involved euthanasia and 
harvesting of bone marrow macrophages. All efforts were made to minimize 
discomfort, pain and distress.  
 
Mouse Strains 
Male ApoE-/- and C57BL/6 wild type mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME). C57BL/6 mice deficient in TLR2 and TLR4 were 
provided by Dr. S. Akira (Osaka University, Osaka, Japan) and bred in house. 
Mice were maintained under specific-pathogen free conditions and cared for in 
accordance with the Boston University IACUC. 
 
Bone Marrow Derived Macrophage Culture and Stimulation 
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Bone marrow derived macrophages (BMDM) from wild-type and knockout mice 
were cultured as described previously (Papadopoulos et al.,2013). Briefly, bone 
marrow was harvested from both the tibia and femur and grown in RPMI 
supplemented with 10% fetal bovine serum (Thermo Scientific HyClone Fetal 
Bovine Serum, Defined SH3007003HI Heat inactivated) and 20% L929 
supernatants containing macrophage colony-stimulating factor (M-CSF). After 7 
days in culture, contaminating nonadherent cells were removed and adherent 
cells were harvested for assays utilizing Cell Stripper (Corning). Cells were 
seeded into 24-well plates at 2X105 cells/well (ELISA assays) or 6-well plates at 
1X106 cells/well (Western blot analysis) and stimulated with bacteria at indicated 
MOI for 18-20h. Cells stimulated with ultra-pure LPS from E. coli OIII:B4 
(InvivoGen San Diego, CA) or Pam3CysSk4 (InvivoGen) served as controls. 
Cells treated with media alone represent unstimulated conditions.  
 
Bacterial Strains and Growth media  
Frozen stocks of P. gingivalis wild-type strain 381 and the lipid A mutants 
(PG1587381 and PG1773381) were grown anaerobically at 37oC on standard blood 
agar plates (Remel) for 3–5 days (Madrigal et al.,2012). Brain heart infusion 
broth (Becton-Dickinson Biosciences) supplemented with yeast extract (0.5%; 
Becton-Dickinson Biosciences), hemin (10 μg/ml; Sigma-Aldrich), and 
menadione (1 mg/ml; Sigma- Aldrich) was inoculated with plate grown bacteria. 
Cultures were grown anaerobically for 16-18h. P. gingivalis lipid A mutants were 
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grown in the presence of erythromycin (5 μg/mL). Cultures were confirmed for 
purity by Gram-stain. 
 
Gene Deletions in P. gingivalis strain 381 
The genomic nucleotide sequences encoding the putative lipid A 1-phosphatase, 
PG1773, and the putative lipid A 4’-phosphatase, PG1587, were obtained from 
searches of the annotated P. gingivalis W83 genome at The Comprehensive 
Microbial Resource (http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi). 
Gene deletions were created by introducing an erythromycin resistance cassette 
(ermF/AM) in place of the coding region for PG1773 and PG1587. Polymerase 
chain reaction (PCR) amplification of genomic DNA from P. gingivalis 381 was 
performed using primer sets designed against the W83 sequence to amplify 1000 
base-pairs upstream and 1000 base-pairs downstream from the regions adjacent 
to the PG1773 and PG1587 coding regions, respectively. The amplified 5’ and 3’ 
flanking regions for PG1773 and PG1587, respectively, were co-ligated with the 
ermF/AM cassettes respectively into pcDNA3.1(-) to generate the gene 
disruption plasmids, p1773 5’flank:erm:3’flank and p1587 5’flank:erm:3’flank. P. 
gingivalis 381 deficient in either PG1587 (PG1587381) or PG1773 (PG1773381) 
was generated by introducing either p1587 5’flank:erm:3’flank or p1773 
5’flank:erm:3’flank into P. gingivalis 381 by electroporation in a GenePulser Xcell 
(BioRad, Hercules, CA).  Bacteria were plated on TYHK/agar plates containing 
erythromycin (5 µg/ml), and incubated anaerobically.  One week later, colonies 
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were selected for characterization.  Loss of the PG1587 and PG1773 coding 
sequences were confirmed in all clones by PCR analyses using primers 
designed to detect the coding sequences in wild-type 381 bacteria. 
 
MALDI-TOF MS Analyses  
LPS and Lipid A from P. gingivalis 381 and the lipid A mutant strains (PG1587381 
and PG1773381) were isolated as previously described by the Darveau laboratory 
at the University of Washington Seattle, WA (Coats et al.,2009a). For MALDI-
TOF MS analyses, lipid A were analyzed in the negative ion mode on an 
AutoFlex Analyzer (Bruker Daltonics Billerica, MA). Data were acquired and 
processed using Flex Analysis software (Bruker Daltonics) (Coats et al.,2009a; 
2011).  
 
HEK293 cell TLR Activation Assays 
HEK293 cells were plated in 96-well plates at a density of 4 x 104 cells per well, 
and transfected the following day with plasmids bearing firelfy luciferase, Renilla 
luciferase, recombinant murine TLR4 and MD-2 or recombinant murine TLR2 
and TLR1 by standard calcium phosphate precipitation. After overnight 
transfection, the test wells were stimulated in triplicate for 4h at 37ºC with the 
indicated doses of LPS isolates or live bacteria. Following stimulation, the 
transfected HEK293 cells were rinsed with phosphate-buffered saline and lysed 
with 50 µl of passive lysis buffer (Promega, Madison, WI). Luciferase activity was 
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measured using the Dual Luciferase Assay Reporter System (Promega, 
Madison, WI). Data are expressed as fold increase of NF-κB-activity which 
represents the ratio of NF-κB-dependent fire-fly luciferase activity to β-Actin 
promoter-dependent Renilla luciferase activity. 
 
Polymyxin B Sensitivity Assays  
BHI broth cultures of wild-type 381 and the lipid A mutant strains were started at 
an optical density of 0.1 at 660nm in the presence or absence of increasing 
concentrations (1, 5, 10, 25, 50 μg/mL) of polymxin B (InvivoGen). After overnight 
growth under anaerobic conditions, growth was assessed spectrophotometrically 
at 660nm (Coats et al.,2009b). 
 
Electron Microscopy  
Overnight broth cultures of P. gingivalis 381 and the lipid A mutants were 
resuspended in PBS and prepared for negative staining by phosphotungstic acid 
(neutral pH).  Fimbriae were visualized by transmission electron microscopy with 
assistance from Dr. Esther Bullitt (Boston University School of Medicine, 
Department of Physiology and Biophysics) (Moreau et al.,2010). 
 
Gingipain Activity Assay  
Lysine-specific (KGP) and arginine-specific (RGP) proteolytic activity of P. 
gingivalis 381 and lipid A mutant strains was determined in whole cultures and 
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supernatant fractions with either N-benzoyl-L-arginine-p-nitroanilide or Z-lysine-p-
nitroanilide (Madrigal et al.,2012). Kinetics of p-nitroanilide formation were 
measured spectrophotometrically at 405nm for 20 min and the Vmax was 
calculated in the linear range of the curve in order to assess change in mOD per 
min.  
 
Growth Curves 
Brain heart infusion broth cultures of P. gingivalis, PG1587381 and PG1773381 
were inoculated at a starting OD of 0.3. Bacterial cultures were grown under 
anerobic conditions and growth was assessed spectrophotometrically at 660nm 
at indicated timepoints over a 48h period.  
 
ATP Assays 
ATP levels were assessed from BMDM stimulated with wild-type 381 or the lipid 
A mutants at an MOI of 100 for 0.5, 1 and 2h as previously described (Xiang et 
al.,2013). Briefly, after bacterial stimulation the culture supernatants were 
harvested and centrifuged for 10m at 1200 rpm. ATP concentrations in the 
supernatants were assayed by utilizing a bioluminescence detection kit 
(Promega) and luciferase activity was measured on a luminometer.  
 
ELISA 
Levels of murine IL-1β (BD Bioscience) and IL-1α (eBioscience) in cell culture 
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supernatants were analyzed by ELISA. Furthermore, ELISA was utilized to assay 
P. gingivalis-specific antibody isotypes IgG1, IgG2b, IgG2c and IgG3 as 
previously described (Hayashi et al.,2012). Briefly, P. gingivalis 381 and the lipid 
A mutants were fixed in 4% paraformaldehyde. Immulon 4HXB plates were 
coated with 10 μg/mL of fixed bacteria. Serial dilutions of mouse serum collected 
at 16wks post infection were plated. Determination of IgG isotypes was 
performed using the C57BL/6 Clonotyping Kit (SouthernBiotech Birmingham, 
AL).  
 
Immunoblotting  
Proteins from cell culture supernatants were precipitated with ethanol at -20oC 
overnight and resuspended in Laemmli sample buffer. Cellular lysates were 
collected in RIPA buffer (Thermo Scientific Waltham, MA) and the protein 
concentrations were determined by a bicinchoninic acid (BCA) protein assay 
(Sigma). Samples were prepared for Western blot analysis in 5X Laemmli 
sample buffer [1.5g sodium dodecyl sulfate (SDS), 3.75mL 1M Tris HCl (pH 6.8), 
0.015g Bromophenol Blue, 7.5mL Glycerol, and 3.75mL ddH2O] diluted to a 1X 
solution in ddH20. Samples (20μg) were separated on 12% SDS-PAGE gels, 
transferred to polyvinyldifluoride (PVDF) membranes, blocked in 5% milk and 
immunoblotted for target proteins. Primary antibodies utilized in this study 
include: IL-1β (H-153) and caspase-1 p10 (M-20) (Santa Cruz Biotechnology 
Dallas, TX) and LC3B, p62 and GFP (Cell Signaling Technologies Danvers, MA). 
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An antibody to β-actin (A1978 Sigma) was used as the loading control. 
Secondary antibodies include HRP-linked anti mouse IgG (GE Amersham 
Buckinghamshire, United Kingdom) and HRP-linked anti rabbit IgG (Cell 
Signaling Technology). Membranes were exposed to enhance 
chemiluminescence (GE Amersham) and signal intensity was documented by 
exposing membranes to film or CCD camera (LAS4000, Fujifilm). Densitometry 
of protein bands was performed in ImageJ (NIH) to compare intensity values 
between experimental conditions.  
 
Antibiotic Protection Assay  
BMDM were stimulated with P. gingivalis or lipid A mutants for 2h and 6h. 
Extracellular nonadherent bacteria were removed by washing with PBS. 
Adherent bacteria were killed by addition of gentamicin (300μg/mL) and 
metronidazole (200μg/mL) for 1hr. After PBS wash, BMDM were lysed with 
HyClone water (Thermo Scientific) for 10 min. Serial dilutions of the lysate were 
plated on blood agar plates and cultured anaerobically for CFU enumeration 
(Wang et al.,2007).  
 
Oral Challenge  
Experiments were performed in two separate cohorts of ApoE-/- mice (total n= 
70). Mice were fed a normal chow diet (Global 2018; Harlan Teklad, Madison, 
WI). Six-week old male mice were treated with a 10-day regimen of antibiotics 
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(Sulfatrim; Hi-Tech Pharmacal) ad libitum in drinking water. Mice were 
challenged by oral application of P. gingivalis and lipid A mutant strains (1X109 
CFU) suspended in vehicle (2% carboxymethylcellulose in PBS) at the buccal 
surface of the maxilla 5 times a week for 3 weeks (Hayashi et al.,2010b; 2011; 
2012). Sham-infected (controls) mice received vehicle application alone. Mice 
were euthanized 16 weeks after the first oral challenge (24wk of age). This time 
is consistent with the timeframe that we have used in our previous studies.  
 
In vivo mouse Magnetic Resonance Angiography 
In vivo imaging of the innominate artery was performed using a vertical-bore 
Bruker 11.7 T Avance spectrometer (Bruker; Billerica, MA) as previously 
described (Hayashi et al.,2011).  Mice were anesthetized with 0.5–2% inhaled 
isoflurane and placed in a vertical 30 mm probe (Micro 2.5). Respiration was 
monitored using a small animal monitoring and gating system (SA Instruments, 
Waukesha, WI). The angiography data was acquired with a fast low-angle shot 
(FLASH) sequence using the following parameters: slab thickness = 1.5 cm; flip 
angle = 45°; repetition time = 20 ms; echo time = 2.2 ms; field of view = 1.5 × 1.5 
× 1.5 cm; matrix = 128 × 128 × 128; number of average = 4. The total scan time 
was ∼25 min. Visualization of the vasculature was achieved by 3D maximum 
intensity projections (MIP) of angiographic images reconstructed using 
Paravision. The target cross section of the innominate artery was chosen at 0.3- 
to 0.5-mm distance below the subclavian bifurcation. Lumen area of the chosen 
  
 
61 
cross section was manually defined and calculated with ImageJ (National 
Institutes of Health) by two independent observers. The intra-reader reliability 
was excellent with interclass correlation coefficient values of 0.91.  
 
Histology and Immunohistochemistry  
Mice were euthanized (n = 3-4/group), perfused with PBS (5mL) and the aortic 
arch with heart tissue was embedded in OCT freezing compound. Seven-
micrometer serial cryosections were collected every 70μm in the innominate 
artery.  Hematoxylin and eosin staining or immunohistochemistry was performed 
on cryosectections corresponding to greatest plaque accumulation in the 
innominate artery as previously described (Hayashi et al.,2011; 2012). Digital 
micrographs were captured at 10X and 40X. Macrophages were identified using 
rat anti-mouse F4/80 (no. MCA497R; Serotec, Oxford, U.K.) or isotype controls 
(no. MCA1125; Serotec). Biotinylated anti-rat (mouse absorbed) IgG was used 
as secondary Ab (Vector Laboratories, Burlin- game, CA). Nuclei were counter-
stained with hematoxylin.  
 
Atherosclerotic Plaque Assessment  
Aortas were harvested and stained with Oil Red O as described (Hayashi et 
al.,2012). Digital micrographs were taken, and total area of atherosclerotic 
plaque was determined using ImageJ (NIH) by a blinded observer. 
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Microcomputed Tomography 
Three-dimensional analysis of alveolar bone loss was assessed as previously 
described (Papadopoulos et al.,2013). Briefly, cephalons were fixed for 24–48 h 
in 4% buffered paraformaldehyde and stored at 4°C in 70% ethanol until 
evaluation by microcomputed tomography (micro-CT). Quantitative three-
dimensional analysis of alveolar bone loss in hemi-maxillae was performed using 
a desktop micro-CT system (µCT 40; Scanco Medical AG, Bassersdorf, 
Switzerland). Maxillary block biopsies were scanned at a resolution of 12 µm in 
all three spatial dimensions. Raw images were converted into high-quality dicoms 
and analyzed using computer software (Amira 5.2.2; Visage Imaging). Residual 
supporting bone volume was determined for the buccal roots. The apical basis of 
the measured volume was set mesio-distally parallel to the cemento-enamel 
junction and bucco-palatinally parallel to the occlusal plane. Results represent 
residual bone volume (mm3) above the reference plane (180 µm from the 
cemento-enamel junction). 
 
Immortalized Bone Marrow Macrophage Cell Line 
Immortalized bone marrow derived macrophages (iBMM) from wild-type C57Bl/6 
stably expressing EGFP-LC3 (GFP-LC3) were a generous gift from Dr. Hardy 
Kornfeld (UMass Medical School) and were generated as previously described 
(Harris et al.,2011). iBMM were grown in RPMI supplemented with 10% fetal 
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bovine serum (Thermo Scientific HyClone Fetal Bovine Serum (U.S.), Defined 
SH3007003HI Heat inactivated).  
Confocal Microscopy for GFP- LC3 Punctae  
iBMM stably expressing GFP-LC3 were seeded on cover glass chamber wells 
(Lab-Tec) at a density of 80,000 cells per well. The next day, cells were 
stimulated with wild-type 381 at an MOI of 10. After bacterial stimulation, the 
media was aspirated and cells were fixed with 4% paraformaldehyde dissolved in 
phosphate buffered saline (PBS) for 15m at room temperature. Fixed cells were 
washed three times with PBS before VectaShield® Mounting Medium with DAPI 
(Vector Labs) was added to each well. GFP-LC3 punctae within iBMM GFP-LC3 
cells were visualized on a Zeiss LSM 700 (Zeiss, Thornwood NY) at 40X 
magnification using a 488 laser. Images were randomly captured with Zen 10 
software. Quantification of GFP-LC3 punctae was performed in FIJI (NIH). At 
least 100 cells were counted for each condition. A threshold of more than 10 
punctae / cell was considered positive for autophagosome formation (Mizushima 
et al.,2010).  
 
Statistical Analysis  
Data were analyzed by two-tailed unpaired Student’s t test or ANOVA with 
Bonferroni’s posttest where indicated for each figure.  p values from .001 to .05 
were considered indicative of statistical significance.  
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Chapter 3. Lipid A expression contributes to TLR4 evasion and attenuation 
of NFκB dependent proinflammatory mediators    
Typically, the host detects Gram-negative bacterial pathogens through sensing 
LPS expressed on bacterial membranes by the innate immune receptor, TLR4 
(Akira et al.,2001; Takeda and Akira, 2004; Kawai and Akira, 2006). However, a 
number of highly successful pathogens have evolved mechanisms to evade 
immune detection at TLR4 through modifications of lipid A, the component of 
bacterial LPS that directly activates TLR4 (Needham and Trent, 2013). It is 
known that P. gingivalis modifies its lipid A to moieties that are altered in their 
acyl chains and terminal phosphate groups, allowing P. gingivalis to function as 
either a weak agonist, antagonist, or non-activating at TLR4 (Kumada et al.,1995; 
Al-Qutub et al.,2006; Reife et al.,2006; Coats et al.,2009a).  Expression of these 
multiple lipid A structures has complicated the interpretation of how the host 
detects P. gingivalis infection at TLR4. Therefore, we constructed lipid A mutant 
strains of P. gingivalis that were “locked” in specific lipid A conformations and 
unresponsive to growth conditions. In this section we report the construction and 
characterization of these resulting strains. Furthermore, we assess the 
production of proinflammatory mediators from macrophages stimulated with wild-
type P. gingivalis and lipid A mutant strains.  
 
 
 
  
 
65 
Characterization of P. gingivalis lipid A mutants 
To confirm that modification of lipid A structures in P. gingivalis strains 
PG1587381 and PG1773381 did not alter the expression of other outer membrane 
components, we examined the major fimbriae protein and activity of the cell-
associated cysteine proteases, gingipain R and gingipain K.  Similar levels of 
fimbriae expression were observed in P. gingivalis strains 381, PG1587381 and 
PG1773381 by both electron microscopy and Western blot analysis (Figure 7A-B) 
(Takahashi et al.,2006). By utilizing an in vitro assay that detects the proteolytic 
activity of P. gingivalis gingipains (Madrigal et al.,2012), we observed a slight 
decrease in gingipain activity (KGP and RGP) in P. gingivalis strain PG1587381 
as compared to that observed in the wild-type strain (Figure 7C). We did not 
observe significant differences in the growth of P. gingivalis strains PG1587381 
and PG1773381 as compared to the wild-type strain (Figure 7D). 
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Figure 7. Fimbriae expression, gingipain activity, and growth of P. 
gingivalis lipid A 1- and 4’ phosphatase mutants. Electron microscopy was 
performed with P. gingivalis wild-type strain 381, PG1587381 and PG1773381 (A). 
Fimbriae expression was examined by Western blot analysis in whole cell lysates 
(5x107 CFU) using a monoclonal antibody to major fimbriae (B). The proteolytic 
activities of the cell-associated cysteine proteases, gingipain R (RGP) and 
gingipain K (KGP) for wild-type 381 and the lipid A mutants PG1587381 and 
PG1773381 in whole cultures (lysate) and supernatant fractions were determined 
by an in vitro gingipain assay  (C). Percent proteolytic activity as compared to P. 
gingivalis wild-type strain 381 gingipain activity for PG1587381 (white bars) and 
PG1773381 (black bars). Bars indicate mean + SEM from three independent 
experiments. Brain heart infusion broth cultures of P. gingivalis wild-type (solid), 
PG1587381 (dotted), and PG1773381 (dashed) were inoculated at a starting 
OD660 of 0.3. Growth was monitored at indicated time points over 48h (n=4) (D).  
 *p< .05, **p<.01; ANOVA with Bonferroni’s posttest. NS indicates not significant.  
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To verify that the mutant 381 strains exhibit phenotypes that are consistent with 
bacterial surface lipid A modifications rather than modifications of other surface 
virulence factors, we assessed the ability of the P. gingivalis wild-type strain and 
the lipid A mutants to activate TLR2. All three P. gingivalis strains induced a 
similarly significant increase in NF-κB activation in HEK293 cells over expressing 
murine TLR2 (Figure 8A). Stimulation of HEK-TLR2 cells with purified LPS 
isolated from the P. gingivalis wild-type strain 381 and the lipid A mutants 
resulted in equivalent activation of TLR2 (Figure 8B). These results were 
expected since P. gingivalis strongly activates TLR2 via expression of fimbriae 
and lipoproteins (Davey et al.,2008; Jain et al.,2013). We observed similar results 
in HEK293 cells overexpressing human TLR2 stimulated with all three P. 
gingivalis strains (Figure 8C); however, we observed a slight decrease in the 
ability of the P. gingivalis wild-type strain 381 to activate TLR2 at lower MOIs 
(Figure 8D).  
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Figure 8. Wild-type P. gingivalis and lipid A mutants equally activate NFκB 
in HEK cells overexpressing TLR2. HEK293 cells overexpressing mouse TLR2 
(A-B) or human TLR2 (C-D) were stimulated with whole bacterium (A,C-D) or 
corresponding LPS concentration purified from each strain (B) overnight. 
Relative NFκB activity indicates inducible firefly luciferase activity over the media 
control. Wild-type P. gingivalis (solid), PG1587381 (dotted), and PG1773381 
(dashed). Graphs show the mean + SEM of triplicate wells and are 
representative of at least two independent experiments. Cells treated with 
Pam3CysSk4 (1µg/mL) or E. coli LPS (100 ng/mL) for 5 h served as a positive 
and negative controls respectively (not shown).  
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P. gingivalis lipid A expression and TLR4 activation 
MALDI analysis of LPS isolated from P. gingivalis strain 381 revealed an ion 
cluster at m/z 1368 (Figure 9A and 9D). This structure represents the non-
phosphorylated and tetra-acylated lipid A species that was predicted to be 
functionally inert at the TLR4 complex (Coats et al.,2009a). Additionally, we 
observed the expression of TLR4 antagonist (m/z 1448) and TLR4 agonist (m/z 
1688 and m/z 1768) structures (Figure 9A and 9E-G). In order to examine the 
role of distinct lipid A species on the induction of inflammation, we constructed P. 
gingivalis strains lacking lipid A 1- and 4’- phosphatase activities in P. gingivalis 
381. MALDI analysis of P. gingivalis strain PG1587381, that lacks 4’-phosphatase 
activity, revealed TLR4 agonist lipid A structures that centered at m/z 1768 and 
m/z 1688 (Figure 9B and 9F-G). MALDI analysis of P. gingivalis strain 
PG1773381, which lacks 1-phosphatase activity, revealed a TLR4 antagonist lipid 
A mass ion that was predominantly centered at ~1448 m/z as well as the 
agonistic lipid A centered at ~1768 m/z (Figure 9C, 9E and 9G).  
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Figure 9. Deletion of P. gingivalis endogenous lipid A 1- and 4’- 
phosphatase activities alters bacterial lipid A expression and TLR4 
activation. Lipid A isolated from P. gingivalis wild-type strain 381 (A) or lipid A 
mutant strains PG1587381 (B) and PG1773381 (C) were examined by MALDI-TOF 
MS. Arrows indicate the predominant lipid A species expressed that are 
expressed for each strain (A-C). The major lipid A structures examined in this 
study have been identified in P. gingivalis as previously described (D-G) 
(Kumada et al.,1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
74 
To confirm the predicted TLR4 activation phenotype of the lipid A expressed by 
wild-type 381 and the lipid A mutants, we stimulated HEK cells that overexpress 
mouse TLR4-MD2 with purified LPS from each strain. Notably, the LPS 
preparations purified from all three strains similarly activated mouse TLR4-MD2 
(Figure 10A). In contrast, when live bacteria were used to stimulate the HEK 
cells only strain PG1587381 resulted in a significant increase in TLR4-dependent 
NF-κB activation as compared to wild-type 381 and PG1773381 (Figure 10B).  
We propose these results might be due to differentially distributed lipid A within 
the bacterial cell membranes depending upon the strains, and that the relative 
localization of the specific agonistic and antagonistic lipid A forms to the outer 
cell membrane determines the respective abilities of the different strains to 
activate TLR4. The less potent lipid A forms (m/z 1368, 1448, 1688) may be 
primarily expressed on the bacterial outer membrane whereas the most potent 
lipid A form (m/z 1768) predominates in the inner membrane where it is initially 
synthesized prior to processing by phosphatases and deacylase(s). Due to 
species specific differences in recognition of lipid A, we also stimulated HEK cells 
that overexpress human TLR4 and observed a similar phenotype as murine 
TLR4. Only strain PG1587381 resulted in a significant increase in TLR4-
dependent NF-κB activation as compared to wild-type 381 and PG1773381 
(Figure 10C).  
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Figure 10. Expression of agonist lipid A by PG1587381 results in activation 
of NFκB in HEK cells overexpressing TLR4. HEK cells overexpressing mouse 
TLR4-MD2 (A-B) or human TLR4 (C) were stimulated overnight with 
corresponding LPS concentration purified from each strain (A) or whole 
bacterium at an MOI of 1, 10 or 100 (B) or 10, 50, 100 (C). Relative NFκB activity 
indicates inducible firefly luciferase activity over the media control. Wild-type P. 
gingivalis (solid), PG1587381 (dotted), and PG1773381 (dashed). Graphs show 
the mean + SEM of triplicate wells and are representative of two independent 
experiments. Cells treated with E. coli LPS (100 ng/mL) or Pam3CysSk4 
(1µg/mL) for 5 h served as positive and negative controls respectively (not 
shown).  
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P. gingivalis lipid A dictates susceptibility to cationic microbial peptides 
In addition to direct impact on TLR4 activation, modifications in lipid A structure 
can significantly alter the ability of cationic peptides to kill bacteria. We have 
previously reported that two different strains of P. gingivalis (33277 and A7436) 
deficient in PG1587 exhibit the most pronounced sensitivity to the cationic 
microbial peptide, polymyxin B, as compared to the wild-type and PG1773 strains 
consistent with a critical role of the lipid A 4’-phosphate in rendering bacteria 
susceptible to this drug (Coats et al.,2009a; 2009b). Assessment of these 
mutations in the 381 strains revealed a comparable pattern. Strain PG1587381 
exhibited a pronounced susceptibility to polymyxin B while the P. gingivalis wild-
type strain 381 and strain PG1773381 were relatively more resistant (Figure 11). 
These data correlate well with the above TLR4 activation data suggesting that 
lipid A structures localized in the outer membrane of the PG1587381 mutant 
contain 4’-phosphate (m/z 1688). In contrast, the PG1773381 strain is the most 
resistant, suggesting the predominance of lipid A lacking 4’-phosphate in the 
outer membrane (m/z 1448). Wild-type 381 has an intermediate polymyxin B 
resistance phenotype consistent with an increased presence of lipid A containing 
4’-phosphate as compared to strain PG1773381. Of note, in the absence of 
polymyxin B, wild-type P. gingivalis and PG1587381 did not grow to the same OD 
as PG1773381 after overnight culture.  
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Figure 11. Lipid A phosphatase activity contributes to P. gingivalis 
susceptibility to cationic microbial peptides. Wild-type 381 and the lipid A 
mutants PG1587381 and PG1773381 were inoculated at an OD660 of 0.1 and 
grown under anaerobic conditions overnight in the presence or absence of PMB 
(1, 5, 10, 25, 50 μg/mL). Growth was measured by spectrophotometry (OD660). 
Wild-type P. gingivalis (solid), PG1587381 (dotted), and PG1773381 (dashed). 
Graphs show the mean + SEM of triplicate wells and are representative of two 
independent experiments.  
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P. gingivalis lipid A expression modulates induction of proinflammatory 
mediators  
To assess the role of lipid A modifications on the production of pro inflammatory 
mediators, we stimulated BMDM with wild-type P. gingivalis and the lipid A 
mutant strains (which equally activate TLR2 but differentially activate TLR4). 
Stimulation of BMDM with P. gingivalis strain PG1587381 resulted in increased 
production of the cytokines IL-1β, IL-1α, IL-6, and the chemokine KC (functional 
homolog of IL-8) compared to P. gingivalis strains 381 and PG1773381 (Figure 
12A-C,E), suggesting that increased immunostimulatory potential at TLR4 
enhances inflammatory mediators.  In contrast, all three P. gingivalis strains 
induced significant levels of the cytokine TNF-α (Figure 12D). This result was 
somewhat anticipated since it has been demonstrated that P. gingivalis-mediated 
TLR2 signaling enhances TNF-α production (Papadopoulos et al.,2013). We 
observed a dose-dependent increase for all inflammatory mediators except for 
IL-6 and KC. BMDM treated with an MOI of 100 resulted in complete depletion of 
these proteins (Figure 12C-E). This result may be due to increased gingipain 
cleavage of IL-6 and IL-8 as previously reported in the literature (Stathopoulou et 
al.,2009).  
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Figure 12. Expression of antagonistic or inert lipid A attenuates the 
production of NFκB-dependent proinflammatory mediators. BMDMs from 
C57BL/6 were stimulated with P. gingivalis wild-type strain 381 (381) or the lipid 
A mutant strains PG1587381  (1587) and PG1773381 (1773) at an MOI of 1 (white) 
10 (gray) and 100 (black). Levels of IL-1β (A), IL-1α (B), IL-6 (C),TNFα (D), and 
KC (E) were assayed by ELISA at 24h. Cells treated with E. coli LPS (100 
ng/mL) for 5 h or E. coli LPS (100 ng/mL) for 5h and ATP (5mM) for 20min 
served as a positive control. Graphs show the mean + SEM of triplicate wells and 
is representative of three independent experiments. *p< .05, **p<.001, 
***p<.0001; ANOVA with Bonferroni’s posttest. NS indicates not significant. ND 
indicates not detected.  
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Role of TLR2 and -4 on induction of proinflammatory mediators 
The role of TLR2 and TLR4 in the production of these inflammatory cytokines 
was assessed in BMDM obtained from TLR2- and TLR4-deficient mice. P. 
gingivalis-induced TNF-α production required both TLR2 and TLR4 signaling; 
however, TLR2 signaling was more dominant (Figure 13D). Additionally, we 
observed that the ability of P. gingivalis to induce IL-1β and IL-1α was dependent 
on both TLR2 and TLR4 signaling (Figure 13A-B). In contrast, P. gingivalis-
induced expression of KC and IL-6 were primarily dependent on TLR4 signaling 
(Figure 13C-E). We observed that PG1587381 induced enhanced KC and IL-6 
levels in TLR2-deficient macrophages as compared to the P. gingivalis wild-type 
strain 381, suggesting the increased cytokine production we observed in wild-
type BMDM was mediated via TLR4 signaling. Furthermore, we observed 
comparable KC and IL-6 levels in BMDM deficient in TLR4 following stimulation 
with all 3 strains of P. gingivalis, suggesting additional signaling through TLR2 in 
the absence of TLR4 or an inability of lipid A to antagonize production of these 
cytokines.   
  
 
84 
 
  
 
85 
Figure 13. Role of TLR2 and TLR4 on P. gingivalis-mediated production of 
proinflammatory mediators from macrophages. BMDMs from wild-type 
C57BL/6 (white), TLR2-deficient (gray), or TLR4-deficient mice (black) were 
stimulated with P. gingivalis wild-type strain 381 or the lipid A mutant strains 
PG1587381 and PG1773381 at an MOI of 100 (A, B, D) or at an MOI of 10 (C, E) 
for 24h.  Levels of IL-1β (A), IL-1α (B), IL-6 (C), TNFα (D), and KC (E) were 
assessed by ELISA. Bars indicate mean + SEM for n=3 sample wells. Cells 
treated with E. coli LPS (100 ng/mL) or Pam3CysSk4 (1µg/mL) for 5 h served as 
a positive control. The addition of ATP to the IL-1β controls served as the second 
signal to activate the inflammasome. Graphs show the mean + SEM of triplicate 
wells and is representative of three independent experiments. *p< .05, **p<.001, 
***p<.0001; ANOVA with Bonferroni’s posttest. NS indicates not significant. ND 
indicates not detected.  
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Chapter Summary 
P. gingivalis expresses an atypical LPS structure comprised of lipid A moieties 
that function as agonist, antagonist or non-activating at TLR4. Expression of 
these divergent structural types depends on local environmental conditions such 
as temperature and levels of hemin (Al-Qutub et al.,2006; Curtis et al.,2011). 
Expression of multiple lipid A structures has complicated the interpretation of how 
the host detects P. gingivalis infection at TLR4. Therefore, we constructed lipid A 
mutants with a deletion of either 1- or 4’ phosphatase activities resulting in strains 
of P. gingivalis that exclusively function as TLR4 agonists (PG1587381) or TLR4 
antagonists (PG1773381). Our results demonstrate that a deletion of PG1587 or 
PG1773 alters the ability of the whole bacteria to activate TLR4 but does not alter 
the expression of other outer membrane components or the ability of the 
pathogen to activate TLR2.  Therefore, the use of strains PG1587381 and 
PG1773381 in this study allowed us to assess the immunological consequences of 
differential lipid A expression by P. gingivalis.   
 
Production of inflammatory mediators from immune cells is critical to activating 
innate immunity and alerting the host to infection (Price and Vance, 2014). Here, 
we observed that expression of antagonistic or inert lipid A attenuates the 
production of NFκB-dependent proinflammatory mediators IL-1β, IL-1α, IL-6 and 
KC from macrophages. Notably, production of IL-1β and IL-1α required both 
TLR2 and TLR4 signaling, whereas IL-6 and KC levels were dependent on TLR4 
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signaling. IL-1β and IL-1α are cytokines that are regulated by the multi-protein 
intracellular complex the inflammasome (Franchi et al.,2009; Broz and Monack, 
2013). Therefore, in the next chapter we will investigate the role of differential 
lipid A expression on activation of the inflammasome.  
 
We observed enhanced production of TNFα levels from macrophages stimulated 
with all three P. gingivalis strains. Work from the Genco laboratory, and others, 
have previously reported that TNF production from macrophages is dependent 
on TLR2 signaling (Ukai et al.,2008; Liang et al.,2011; Papadopoulos et 
al.,2013). Furthermore, wild-type P. gingivalis and the lipid A mutants all activate 
TLR2 presumably through expression of lipoproteins and fimbriae (Davey et 
al.,2008; Jain et al.,2013). Therefore, this result was somewhat anticipated. 
Collectively, these findings indicate increased immunostimulatory potential at 
TLR4, through expression of agonist lipid A, enhances the production of a 
number of NFκB dependent proinflammatory mediators.  
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Chapter 4. Lipid A expression facilitates evasion of the inflammasome and 
attenuates IL-1β production 
IL-1β is a pro inflammatory cytokine critical to innate immunity due to its role in 
activating signaling cascades that alerts the host to infection (Taxman et 
al.,2010).  Initially, IL-1β is transcribed as an inactive zymogen, downstream of 
TLR ligation (Martinon et al.,2002). Subsequently, IL-1β becomes cleaved to its 
mature and active form upon activation of the multiprotein complex, the 
inflammasome (Lamkanfi, 2011). Cleavage of pro IL-1β to its mature form results 
in the loss of the pro peptide sequence required for conventional secretion 
through the endoplasmic reticulum (Dubyak, 2012). Recently, studies have 
revealed that IL-1β is released by an unconventional secretion system that relies 
on autophagosomes (Dupont et al.,2011), adding additional complexity to how 
the cell regulates IL-1β production (Harris) .  
 
Due to its significant role in innate defense, it is not surprising that a number of 
pathogens have evolved mechanisms to dampen or inhibit IL-1β production 
(Taxman et al.,2010). In the case of P. gingivalis, it is well documented that this 
pathogen does not induce significant levels of IL-1β production from 
macrophages (Yilmaz et al.,2008; Taxman et al.,2012). Thus, the increased 
production of IL-1β observed in macrophages stimulated with the P. gingivalis 
TLR4 agonist strain (PG1587381) was an unexpected finding. Due to the role of 
TLR stimulation on production of the pro form of IL-1β, we sought to investigate 
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levels of pro IL-1β in macrophages stimulated with wild type 381 and the lipid A 
mutants. Surprisingly, we observed that all three P. gingivalis strains induced 
expression of pro IL-1β (Figure 14A), which was dependent on TLR2 (Figure 
14B) and TLR4 (Figure 14C). These results indicate that the attenuated 
production of IL-1β observed with P. gingivalis strains 381 and PG1773381 was 
not due to an obstruction of TLR-mediated synthesis of pro-IL-1β.  
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Figure 14. P. gingivalis induction of Pro-IL-1β requires TLR2 and TLR4 
signaling. Western blot analysis for the pro form of IL-1β was performed on 
BMDM lysates from wild-type C57BL/6 (A) TLR2 (B) and TLR4 (C) deficient mice 
stimulated with increasing MOI (1, 10, 100) of wild-type 381 or the lipid A mutant 
strains overnight.  BMDMs treated with media alone (Unstim), with E. coli LPS 
(100 ng/mL) for 5h and then ATP (5 mM) for 20m, or Pam3CysSk4 (Pam3, 
1µg/mL) for 5 h and then ATP (5 mM) for 20m served as the negative and 
positive controls. Immunoblots are representative of at least two independent 
experiments.  
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ATP levels in BMDM stimulated with P. gingivalis and lipid A mutants 
These findings led us to investigate the role of P. gingivalis lipid A modifications 
on inflammasome activation, the second signal required for production of mature 
and active IL-1β. The inflammasome is a multiprotein intracellular complex that is 
activated by a number of sterile activators that include both host and environment 
derived molecules or pathogen-associated activators (Davis et al.,2011). 
Activation of the inflammasome results in active caspase-1, which subsequently 
proteolytically cleaves pro IL-1β to its mature and active form.  A common 
activator of the inflammasome is ATP. Although ATP is abundant in all cell types, 
it does not usually exist extracellularly under “normal” conditions (Xiang et 
al.,2013). However, studies have reported that bacteria-infected cells release 
ATP (Säve and Persson, 2010; Xiang et al.,2013).  A previous study documented 
that P. gingivalis is able to scavenge ATP in gingival epithelial cells (Yilmaz et 
al.,2008). Removal of this danger signal from the cell could potentially prevent 
inflammasome activation during P. gingivalis infection.  Therefore, we sought to 
investigate extracellular ATP levels from BMDM stimulated with wild-type 381 
and the lipid A mutants. We observed that uninfected cells alone and bacteria 
released ATP (Figure 15A-C). The quantity of ATP released by the bacteria-
infected cells was not substantially different between the three P. gingivalis 
strains (Figure 15D), suggesting that lipid A modifications do not play a role in 
ATP released from BMDM. Furthermore, the increased production of IL-1β we 
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observed in BMDM stimulated with PG1587381 was not due to enhanced ATP 
production.  
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Figure 15. P. gingivalis expression of lipid A does not affect ATP 
production from macrophages. BMDM were stimulated with wild-type 381 (A), 
PG1587381 (B), and PG1773381 (C) for .5, 1 or 2h. ATP levels were assessed in 
cell supernatants from unstimulated BMDM (white bars), bacteria (gray bars), or 
BMDM stimulated with bacteria (black bars). (D) Represents ATP levels from 
unstimulated BMDM (white bars),or BMDM stimulated with wild-type 381 (light 
gray),  PG1587381 (gray), or PG1773381 (black) at .5, 1 or 2h. RFU indicates 
relative fluorescent units. Bars indicate mean +/- SEM from triplicate wells and 
represents three independent experiments.  
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Role of Non-Canonical Inflammasome in P. gingivalis infection  
We next investigated activation of the inflammasome in BMDM stimulated with 
wild-type 381 and the lipid A mutant strains by assessing caspase-1 levels. 
Notably, stimulation of macrophages with P. gingivalis strain PG1587381 resulted 
in activation of the inflammasome, as assessed by detection of the active 
caspase-1 p10 subunit in cell supernatants by Western blot analysis (Figure 
16A). A non-canonical pathway for inflammasome activation has been recently 
revealed with Gram-negative bacterial infections, which relies on activation of the 
protein caspase-11 upstream of caspase-1 (Rathinam et al.,2012; Broz and 
Monack, 2013). We thus examined the role of caspase-11 in P. gingivalis-
induced IL-1β production. We observed IL-1β production was completely ablated 
in macrophages deficient in caspase-11 following stimulation with P. gingivalis 
strain PG1587381 (Figure 16B), while TNFα levels were not altered (Figure 16C). 
These results indicate that P. gingivalis expression of modified lipid A facilitates 
evasion of the non-canonical inflammasome through a caspase-11 mediated 
pathway.  
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Figure 16. P. gingivalis expression of antagonist lipid A facilitates evasion 
of the inflammasome through a caspase-11 mediated pathway. C57BL/6 WT 
BMDM were stimulated with P. gingivalis wild-type strain 381 or the lipid A 
mutant strains PG1587381 and PG1773381 at increasing MOIs (1, 10, and 100). 
Western blot analysis was performed on BMDM cell lysates to assess levels of 
the proform of IL-1β, pro Caspase-1 and β-actin at 24h (A).  Levels of mature IL-
1β and active caspase-1 (p10) were detected in cell supernatants (A).  BMDM 
from wild-type (white bars) and caspase-11-deficient (black bars) mice were 
stimulated with P. gingivalis wild-type strain 381 or the lipid A mutants at an MOI 
of 100 and levels of IL-1β (B) and TNFα (C) were assessed by ELISA at 24h.  
BMDMs treated with media alone (Unstim) or with E. coli LPS (100 ng/mL) for 5h 
and then ATP (5 mM) for 20m (LPS + ATP) served as the negative and positive 
control respectively. Graphs depict the mean + SEM of triplicate wells and are 
representative of at least three independent experiments. * p< .05 **p<.001 
***p<.0001; two-tailed unpaired t-tests.  
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Downstream events associated with non-canonical inflammasome 
activation  
Active caspase-11 also induces cell lysis (Miao et al.,2010), resulting in release 
of danger signals, such as the proinflammatory cytokine IL-1α (Kayagaki et 
al.,2011). We observed an increase in macrophage cell lysis as indicated by 
lactate dehydrogenase (LDH) release following stimulation with P. gingivalis 
strain PG1587381 as compared to stimulation with wild-type 381 and PG1773381 
(Figure 17). Macrophage cell lysis was dependent on both bacterial MOI (Figure 
17A) and time (Figure 17B).  These results correlate well with the increased 
production of IL-1α we observed from BMDM stimulated with PG1587381 
(Chapter 3). To elucidate the role of caspase-11 in P. gingivalis-mediated IL-1α 
production, we stimulated BMDM from caspase-11 deficient mice with all three P. 
gingivalis strains. We observed decreased production of IL-1α following 
stimulation of BMDM obtained from caspase-11-deficient mice with P. gingivalis 
strain PG1587381 (Figure 18). Interestingly, we did not observe significant 
differences in the levels of IL-1α in BMDM obtained from caspase-11-deficient 
mice when stimulated with wild-type 381 compared to strain PG1587381 (Figure 
18), suggesting distinct mechanism(s) for IL-1α production independent of lipid A 
modifications.  
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Figure 17. Expression of antagonistic or inert lipid A attenuates 
macrophage cell lysis. BMDMs from C57BL/6 were stimulated with P. gingivalis 
wild-type strain 381 (381) or the lipid A mutant strains PG1587381 (1587) and 
PG1773381 (1773) at an MOI of 1 (white) 10 (gray) and 100 (black) for 24h (A) 
or at an MOI 100 for 2h (white), 6h (gray) and 24h (black) (B). Cell lysis was 
assessed by quantifying LDH release (Promega) in cell supernatants. Unstim 
refers to media control. E. coli LPS (100 ng/mL) and ATP (5 mM) served as 
controls. Bars indicate mean +/- SEM from triplicate wells. Graphs represent 
three independent experiments. NS; Not Significant. *p< .05 **p<.001 ***p<.0001; 
ANOVA with Bonferroni’s posttest.  
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Figure 18. Activation of caspase-11 by P. gingivalis lipid A contributes to 
IL-1α production from macrophages. BMDM from wild-type (white bars) and 
caspase-11 deficient mice (black bars) were stimulated with P. gingivalis wild-
type strain 381 or the lipid A mutant strains PG1587381 and PG1773381 at an MOI 
of 100 for 24h and IL-1α levels were assessed by ELISA. Unstim refers to media 
control. E. coli LPS (100 ng/mL) for 5h and ATP (5 mM) for 20min served as a 
negative control. Bars indicate mean +/- SEM from replicate wells. Graph 
represents two independent experiments. NS; Not Significant. *p< .05 **p<.001 
***p<.0001; ANOVA with Bonferroni’s posttest.  
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Inflammasome evasion and bacterial survival  
Pathogen evasion of inflammasome activation has been proposed to serve as a 
dual role: to prevent IL-1β release and to circumvent host cell death in order to 
provide an intracellular niche for the pathogen to survive (Taxman et al.,2010; 
Shimada et al.,2012). Therefore, we assessed the intracellular survival of P. 
gingivalis and the lipid A mutants in BMDM at 2h and 6h. We observed a 
decrease in survival of P. gingivalis strain PG1587381 in macrophages compared 
to P. gingivalis strains 381 and strain PG1773381 at 2h (Figure 19). After 6h of 
infection, bacterial survival significantly declined for all P. gingivalis strains 
(Figure 19). These results indicated that P. gingivalis evasion of inflammasome 
activation, via expression of antagonist lipid A, not only contributes to attenuated 
IL-1β production but also contributes to bacterial survival.  
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Figure 19. P. gingivalis expression of antagonist lipid A facilitates bacterial 
survival. C57BL/6 WT BMDM were stimulated with P. gingivalis wild-type strain 
381 or the lipid A mutant strains PG1587381 and PG1773381 at an MOI of 10 (A) 
or MOI of 100 (B) for 2h (white) or 6h (gray). Viable counts (CFU) of internalized 
P. gingivalis were determined by plating serial dilutions of macrophage lysates on 
blood agar plates. % Viability refers to the percentage of recovered CFUs 
normalized to the bacterial input. Bars indicate +/- SEM from six replicates from 
one experiment. Graph represents two independent experiments. NS; Not 
Significant. *p< .05 **p<.001 ***p<.0001; ANOVA with Bonferroni’s posttest.  
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Role of lipid A expression on autophagy-mediated IL-1β release  
Thus far we have observed that P. gingivalis expression of antagonist lipid A 
contributes to evasion of the non-canonical inflammasome and attenuated 
production of IL-1β from macrophages. We next sought to investigate whether P. 
gingivalis played a role in autophagy-mediated IL-1β secretion. It is important to 
note that there is a complex interplay between autophagy and IL-1β release. 
Autophagy is a constitutively active process and under basal conditions functions 
to inhibit unwarranted IL-1β release by targeting components of the 
inflammasome complex for autophagic degradation (Nakagawa et al.,2004; 
Harris et al.,2011; Zhou et al.,2011). However, upon autophagy activation, 
Dupont et al have shown that autophagy functions to facilitate the unconventional 
secretion of IL-1β (Dupont et al.,2011). In this study, BMDM undergoing active 
autophagy (by starvation conditions) were treated with an inhibitor to 
autophagosome / lyososmal fusion (bafilomycin). The result was decreased IL-1β 
secretion in cells treated with bafilomycin versus untreated cells, suggesting that 
autophagy functions to mediate IL-1β release. In this study, if induction of 
autophagy had acted to degrade IL-1β, then bafilomycin treatment would have 
increased IL-1β levels. This result was only observed when cells were 
undergoing induced autophagy by starvation, not under basal autophagy 
conditions, supporting the previous reports that have demonstrated that basal 
autophagy functions to inhibit unwarranted inflammasome activation and IL-1β 
secretion (Nakahira et al.,2011; Zhou et al.,2011).  
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Given these reports, we utilized comparable experimental conditions as reported 
by Dupont et al in order to evaluate the role of P. gingivalis on autophagy-
mediated IL-1β secretion. Since we have observed very low levels of IL-1β with 
wild-type 381 and the lipid A antagonist strain PG1773381, we chose to only use 
these strains in the following experiment. Induction of autophagy in BMDM by 
starvation (EBSS), followed by treatment with bafilomycin resulted in increased 
IL-1β compared to autophagy active BMDM not treated with bafilomycin (Figure 
20, Starvation). These results suggest that following induction of autophagy, IL-
1β is degraded in BMDM stimulated with 381 and PG1773381.  However, this 
result was only statistically significant with strain PG1773381 and this experiment 
has only been performed one time. Similar to the Dupont et al study, this result 
was not observed in cells that were not undergoing active autophagy (Figure 20, 
Complete Media). Therefore, these results suggest that during active stages of 
autophagy, P. gingivalis reroutes the cellular pool of autophagosomes to 
attenuate secretion of IL-1β.  
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Figure 20. P. gingivalis 381 and PG1773381 obstruct autophagy mediated IL-
1β secretion. BMDM were stimulated with 381 or PG1773381 at an MOI of 10 
overnight and then stimulated with media alone (control, white bars) or 
bafilomycin (100nM, black bars). Autophagy was induced by starvation with 
EBSS (Starvation) for 1hr. Samples without EBSS treatment are indicated as 
Complete Media. IL-1β levels were assessed by ELISA. Bars indicate +/- SEM 
from replicate wells and represent one experiment. ***p<.001; NS indicates no 
significance. Two-way ANOVA 
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Since Dupont et al. reported that under autophagy activation extracellular IL-1β 
levels increase, we sought to investigate whether if enhanced autophagy, by 
pharmacological activation, would increased IL-1β levels in macrophages 
stimulated with P. gingivalis. Therefore, we stimulated BMDM with P. gingivalis in 
the presence or absence of the autophagy activator, rapamycin. We observed an 
increase in IL-1β levels in BMDM stimulated with P. gingivalis and rapamycin 
compared to P. gingivalis stimulation alone, however this affect was only 
observed when BMDM were treated with P. gingivalis at an MOI of 10  (this result 
was not statistically significant) (Figure 21). Interestingly, when cells were 
treated with P. gingivalis at an MOI of 100, we observed a significant decrease in 
IL-1β production. However, we also observed this same decrease when cells 
were stimulated with the DMSO control, suggesting that this affect is not due to 
rapamycin treatment, but is actually due to treatment with DMSO.  This was an 
interesting finding because we stimulated cells with a very low concentration of 
rapamycin (3nM) and consequently a low dose of DMSO (.1%).  Therefore, 
future studies will need to investigate other doses of rapamycin that allows for a 
lower DMSO concentration. Under these current conditions, it appears that 
rapamycin does not facilitate the release of IL-1β in BMDM stimulated with P. 
gingivalis due to the off target affects we observe with DMSO.  
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Figure 21. Activation of autophagy with rapamycin does not affect IL-1β 
production in BMDM stimulated with P. gingivalis. BMDM were stimulated 
overnight with P. gingivalis at either an MOI of 10 or 100 in the presence (black 
bars) or absence (white bars) of rapamycin (3nM) overnight. Grey bars indicate 
DMSO control. Graph represents mean +/- SEM of triplicate wells from one 
experiment. ***p<.001; NS indicates no significance. Two-way ANOVA.  
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Although autophagy is known to regulate secretion of IL-1β, there is little 
knowledge on the ability of pathogens to regulate IL-1β levels by targeting 
autophagy.  To date, there has only been one report in macrophages utilizing live 
bacteria that investigated the role of autophagy on IL-1β release. Shi et al. have 
demonstrated that infection of BMDM with M. tuberculosis (a bacterium that is 
known to suppress IL-1β production) and the autophagy inhibitor 3- 
methyladenine (3-MA) led to increased IL-1β production after infection (Shi et 
al.,2012).  
 
Utilizing comparable experimental conditions as Shi et al, we proposed that 
stimulation of macrophages with wild-type P. gingivalis in addition to stimulation 
with the autophagy inhibitor 3-MA would result in increased levels of IL-1β 
secretion, since both M. tuberculosis and P. gingivalis have been documented to 
obstruct IL-1β levels. However, we observed the opposite affect. Treatment of 
BMDM with P. gingivalis and 3-MA resulted in a decrease in IL-1β compared to 
treatment with P. gingivalis alone (Figure 22A). This result was only significant 
when cells were stimulated with an MOI of 10.  In this experiment we utilized a 
5mM concentration of 3-MA, because this concentration has been frequently 
reported as an appropriate “working concentration” for this compound (Yang et 
al.,2013). However, a 5mM treatment resulted in a 10% DMSO solution, which is 
a very high concentration of DMSO. Therefore, we repeated this experiment, 
utilizing a 10-fold decrease in concentration (.05mM 3-MA; .01% DMSO).  Under 
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these conditions, we observed a similar trend as the previous experiment, where 
IL-1β levels decreased in the presence of 3-MA and P. gingivalis, however this 
result was only statistically significant at an MOI of 100 (Figure 22B).  
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Figure 22. Inhibition of autophagy with 3-MA results in decreased IL-1β 
production induced in BMDM stimulated with P. gingivalis. BMDM were 
stimulated overnight with P. gingivalis at either an MOI of 10 or 100 in the 
presence (black bars) or absence (white bars) of 3-MA (5mM, A) or (.05mM, B) 
overnight. Grey bars indicate DMSO control. Graph represents mean +/- SEM of 
triplicate wells from one experiment. *p<.05; **p<.01; ***p<.001; NS indicates no 
significance. Two-way ANOVA.  
  
 
118 
Due to off target affects of utilizing autophagy inhibitors / activators we next 
assessed the levels of additional pro inflammatory cytokines, including IL-6 and 
TNFα. Stimulation of BMDM with 3-MA in the presence of P. gingivalis resulted in 
decreased levels of TNFα and IL-6 (Figure 23); suggesting that there are off 
target affects from using 3-MA. We did not observe any significant changes in 
TNFα and IL-6 from BMDM stimulated with P. gingivalis and rapamycin 
compared to P. gingivalis alone. For the DMSO control for both 3-MA and 
rapamycin we observed a decrease in TNFα and IL-6 (Figure 23), suggesting 
that DMSO alone is affecting the normal function of the macrophage. Therefore, 
future studies designed to address the role of autophagy in P. gingivalis 
mediated secretion of IL-1β will have to utilize different concentrations of both 
rapamycin and 3-MA in order to lower the DMSO concentration. Furthermore, 
these results will need to be confirmed in autophagy deficient cells due to the 
pleiotropic affects of compounds that either activate or inhibit autophagy (Yang et 
al.,2013).  
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Figure 23. Levels of TNFα and IL-6 in BMDM sitmulated with P. gingivalis 
and 3-MA or rapamycin.  BMDM were stimulated overnight with P. gingivalis at 
an MOI of 10 in the presence of DMSO, rapamycin (3nM) or 3-MA (.05mM). 
Graph represents mean +/- SEM of triplicate wells from one experiment. *p<.05; 
NS indicates no significance. One-way ANOVA.  
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Chapter Summary  
Previous studies have documented that P. gingivalis fails to induce significant 
levels of IL-1β production in macrophages (Yilmaz et al.,2008; Taxman et 
al.,2012).  We demonstrate here that P. gingivalis expression of agonist lipid A 
results in increased production of IL-1β from macrophages as compared to P. 
gingivalis expressing non-activating / antagonist lipid A. Enhanced levels of IL-1β 
was due to activation of the inflammasome, through a caspase-11 mediated 
pathway. Our results coincide well with recent reports that have identified a new 
non-canonical inflammasome, mediated by caspase-11, which is activated during 
Gram-negative bacterial infections.  
 
Activation of caspase-11 not only induces caspase-1 dependent maturation of 
pro IL-1β, but it also induces cell lysis, resulting in the release of danger signals 
such as the proinflammatory cytokine IL-1α (Broz and Monack, 2013). We 
revealed that expression of non-activating / antagonist lipid A results in 
decreased levels of IL-1α and cell lysis. We also observed that evasion of the 
inflammasome, through expression of non-activating / antagonist lipid A, 
facilitates bacterial survival in the macrophage. These results point to a dual role 
for evasion of the inflammasome by P. gingivalis: attenuated production of 
inflammatory mediators and preservation of an intracellular bacterial niche. 
Collectively, these findings indicate that in addition to evasion of TLR4 signaling, 
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lipid A modifications promote evasion of the non-canonical inflammasome and 
obstruct downstream events associated with activation of this complex.  
 
We further assessed IL-1β regulation in macrophages stimulated with P. 
gingivalis by assessing autophagy-mediated IL-1β secretion. Although, it is 
known that IL-1β is secreted through an unconventional pathway that is mediated 
by autophagosomes (Dupont et al.,2011), the ability of pathogens to intercept 
this secretory pathway is unknown. Our studies with bafilomycin suggests that P. 
gingivalis, under active autophagy conditions, may intercept autophagosome-
mediate secretion of IL-1β, however additional studies will need to be performed 
in order to confirm this result.  
 
We also utilized the autophagy activator, rapamycin, and the inhibitor, 3-MA, to 
assess IL-1β secretion in the presence of P. gingivalis stimulation. These results 
remain inconclusive, due to the non-specific effect of 3-MA in regulating levels of 
other pro inflammatory cytokines including TNFα and IL-6. Furthermore, there 
appears to be effects of the solvent DMSO, making the results difficult to 
interpret. The role of P. gingivalis on IL-1β secretion should be studied in 
autophagy deficient cells due to the pleiotropic affects of compounds that either 
activate or inhibit autophagy (Mizushima et al.,2010; Yang et al.,2013).  
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Chapter 5. Lipid A expression differentially influences local and systemic 
inflammation 
Due to the challenges of linking periodontal disease to atherosclerosis 
progression in humans, animal models utilizing hypercholesterolemic mice have 
been extremely advantageous (Hansson and Hermansson, 2011). Mice are 
naturally resistant to atherosclerosis; therefore, animal models have been 
designed with targeted deletions of genes encoding molecules involved in 
cholesterol metabolism. Two of the most common mouse models used for 
atherosclerosis studies are the ApoE-/- mice, which have a deletion of 
apolipoprotein E (ApoE) (O'Neill, 1997) and the LDLR-/- mice which have a 
deletion of the low density lipoprotein receptor (LDLR) (Powell-Braxton et 
al.,1998).  
 
Our laboratory has extensive experience utilizing the ApoE-/- mouse with P. 
gingivalis infection (Figure 24). Mice are given a two-week oral regimen of 
antibiotics (Sulfatrim) in order to clear the normal flora (Figure 24).  After a two-
day antibiotic free period, we orally infect mice with P. gingivalis suspended in 
carboxymethylcellulose (CMC) five times a week for three weeks (Figure 24) 
(Gibson et al.,2004; Hayashi et al.,2010b; 2011; 2012). Sham-infected control 
animals receive CMC alone. During the course of the study we monitor plaque 
progression by MRI analysis (Figure 24) (Hayashi et al.,2011). At 16 weeks post 
initial infection we sacrifice mice and harvest maxillae for measurement of oral 
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bone loss by Micro CT (Papadopoulos et al.,2013), aortas for plaque 
accumulation by Oil Red O, and serum for P. gingivalis specific antibodies 
(Figure 24).  
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Figure 24. Outline for P. gingivalis oral challenge in ApoE-/- mice.  Six-week 
old male ApoE-/- mice receive oral antibiotics for ten days followed by a two-day 
rest period. P. gingivalis resuspended in CMC is topically applied to the buccal 
surface of the maxillary gingiva of mice five times a week for three weeks. Sham-
infected control mice receive CMC alone. MRI analysis is performed in order to 
assess plaque progression throughout the course of the study. At 16 weeks post 
initial infection, mice are sacrificed and maxillae are harvested for oral bone loss 
analysis, aortas for plaque accumulation and serum for P. gingivalis-specific 
antibodies.  
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By utilizing this model we have demonstrated that oral infection of ApoE-/- mice 
with P. gingivalis results in chronic inflammation at both local (oral bone loss) and 
systemic sites (atherosclerosis) (Gibson et al.,2004). We have also revealed a 
role for TLR2 and -4 signaling on P. gingivalis induction of chronic inflammation 
in vivo.  ApoE-/- mice deficient in the innate immune receptor TLR2 exhibited 
diminished chronic inflammation and atherosclerosis following P. gingivalis oral 
infection compared to ApoE-/- mice (Hayashi et al.,2010b). In contrast, mice 
deficient in TLR4 exhibited exacerbated atherosclerosis (Hayashi et al.,2012). 
These results indicate that TLR2 signaling is detrimental to P. gingivalis-
mediated chronic inflammation while TLR4 signaling potentially plays a protective 
role. To further evaluate the role of TLR4 on P. gingivalis mediated chronic 
inflammation, we orally infected ApoE-/- mice with wild-type P. gingivalis and the 
lipid A mutant strains that either activate (PG1587381) or are antagonizing 
(PG1773381) at TLR4. In this section we report our findings on the role of 
differential activation of TLR4 by P. gingivalis modified lipid A on mediating oral 
bone loss and systemic inflammation in ApoE-/- mice.  
 
Plaque progression in the innominate artery  
Plaque accumulation in the innominate artery was examined by magnetic 
resonance angiogram (MRA) throughout the course of the study to assess 
progression of site-specific inflammatory atherosclerosis. The innominate artery 
exhibits a high degree of lesion progression and expresses features of human 
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disease including vessel narrowing and perivascular inflammation (Hayashi et 
al.,2011).  MRA at 8wks after initial oral infection resulted in an increase in the 
change of luminal area for mice infected with all 3 strains (Figure 25A). Body 
weight measurements indicate that the mice were still growing at this age, which 
may contribute to the increased luminal area we observed at this timepoint. (14-
16wks of age) (Figure 25B).  At 16wks after oral infection, MRA revealed that 
oral infection with P. gingivalis strains 381 and strain PG1773381 resulted in 
significant luminal narrowing compared to sham-infected controls (Figure 25). In 
contrast, oral infection with P. gingivalis strain PG1587381 induced minimal 
luminal narrowing compared to sham-infected controls (Figure 25).  
Normalization of the change in luminal area to the 8wk lumen area resulted in 
significantly more luminal narrowing from 8 to 16wks for P. gingivalis strains 381 
and PG1773381 compared to strain PG1587381 and sham-infected controls 
(Figure 25 inset).  
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Figure 25. Expression of immunologically silent or antagonistic lipid A 
structures exacerbates atherosclerotic plaque progression in the 
innominate artery. Innominate arteries of ApoE-/- mice were imaged by MRA at 
baseline (wk 0) and at 8 and 16 wk after first oral infection (A) and body weights 
were recorded (B). The temporal change in luminal area (mm2) was calculated 
for individual mice normalized to baseline luminal area (n = 10-12/group). Sham-
infected control ApoE-/- (orange); 381-infected ApoE-/- (black); PG1587381-
infected ApoE-/- (blue); PG1773381- infected ApoE-/- (red). Inset - the temporal 
change in luminal area calculated for individual mice normalized to 8wk luminal 
area (n=10-12/group) Bars indicate +/- SEM.  Two-tailed unpaired t-tests; 
*p<.01**p<.001***p<.0001 compared to sham-infected and PG1587381-infected 
mice.  
 
 
 
 
 
 
 
 
 
  
 
131 
Histological assessment of innominate artery 
Plaque progression in the innominate artery was further assessed in postmortem 
sections by histology. Hematoxylin and eosin staining of tissue sections from the 
innominate artery, corresponding to the region of MRA analysis, revealed partial 
occlusion of the lumen in ApoE-/- mice infected with P. gingivalis strain 381 
(Figure 26A), in agreement with our previous studies (Hayashi et al.,2010b; 
2011; 2012). Oral infection with P. gingivalis strain PG1773381 resulted in plaque 
accumulation that was comparable to that observed with P. gingivalis strain 381 
(Figure 26A). Oral infection with P. gingivalis strain PG1587381 resulted in some 
thickening of the vessel wall but no occlusion of the vasculature (Figure 26A).  
 
Since macrophages play an essential role in plaque progression in 
atherosclerosis, we next assessed macrophage infiltrate into the atherosclerotic 
lesions. Histological sections of the innominate artery were stained with the 
macrophage marker F4/80. We found oral infection with P. gingivalis strains 381 
and PG1773381 resulted in an increase in macrophage accumulation in the 
innominate lesions compared to that observed with P. gingivalis strain PG1587381 
and sham-infected controls (Figure 26B). These results indicate that expression 
of antagonist / agonist lipid A results in an accumulation of plaque in the 
innominate artery which contains a significant influx of macrophages.  
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Figure 26. Plaque accumulation in the innominate artery following oral 
infection of ApoE-/- mice with P. gingivalis and lipid A mutants. 
Representative images of the innominate artery from ApoE-/- mice sacrificed at 
16wk post initial P. gingivalis infection.  (A) Hematoxylin and eosin staining or (B) 
F4/80 staining (macrophages stain brown) and hematoxylin counterstaining for 
each group at 10X and 40X  (n=3/group). 40X images allow for visualization of 
intima, media and adventitia and correspond to the red box depicted in the 10X 
images.  
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Plaque accumulation in the aorta 
We next assessed plaque accumulation in the entire aorta, from the aortic arch to 
the iliac bifurcation. Lipid staining by Oil Red O of en face aortas revealed that 
oral infection with P. gingivalis strains 381 and PG1773381 accelerated plaque 
accumulation compared to that observed in sham-infected mice (Figure 27).  In 
contrast, oral infection with P. gingivalis strain PG1587381 induced minimal 
plaque accumulation (Figure 27).  
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Figure 27. Expression of immunologically silent or antagonistic lipid A 
structures exacerbates atherosclerotic plaque progression in the aorta. 
Plaque area was determined from Oil Red O staining for lipids in en face aortic 
lesions from the aortic arch to iliac bifurcation (Sections I-IV) 16 wk after first 
infection from (A) sham-infected (B) wild-type 381 (C) PG1587381  and (D) 
PG1773381. (E) Quantification of lipid content within total aorta was calculated 
using ImageJ software (NIH) (n=8/group). * p< .05; Students unpaired t-tests.  
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Humoral Response 
To rule out the possibility that the inability of P. gingivalis strain PG1587381 to 
illicit inflammatory disease pathology was due to failed activation of the adaptive 
response, we determined the humoral response in mice infected with each of the 
P. gingivalis strains. Assessment of P. gingivalis specific IgG subtypes in serum 
revealed that the humoral response induced by P. gingivalis strain PG1587381 
was comparable to P. gingivalis strains 381 and strain PG1773381 (Figure 28).  
However, we did observe a slight decrease in the IgG1 response for PG1587381 
and PG1773381 compared to wild-type 381 (Figure 28A).  
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Figure 28. Humoral response following oral infection of ApoE-/- mice with P. 
gingivalis. P. gingivalis-specific antibody isotypes IgG1 (A), IgG2b (B), IgG2c 
(C) and IgG3 (D) were measured in serum by ELISA at 16wk post-infection of 
ApoE-/- mice with P. gingivalis wild-type strain 381 and the lipid A mutants 
PG1587381 and PG1773381 (n=10-12 mice/group). * p< .05 **p<.001; two-tailed 
unpaired t-tests.  
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Inflammatory oral bone loss  
Lastly, we assessed induction of inflammatory alveolar bone loss from ApoE-/- 
mice infected with P. gingivalis strains 381, PG1587381, and PG1773381. 
Interestingly, all three P. gingivalis strains induced oral bone loss to a similar 
extent (Figure 29). These results are consistent with studies demonstrating a 
predominant role for TLR2 signaling in P. gingivalis-induced oral inflammatory 
bone loss (Burns et al.,2006; Ukai et al.,2008; Papadopoulos et al.,2013). 
Darveau et al. have recently shown in a rabbit model of periodontitis, that P. 
gingivalis lipid A mutant strains induce periodontitis that is comparable to wild-
type P. gingivalis (strain A7436); however, each strain induced different microbial 
communities in the oral cavity (Zenobia et al.,2014). These results suggest that 
multiple dysbiotic oral microbial communities can elicit periodontitis. Whether P. 
gingivalis and the lipid A mutants induce a similar dysbiosis to induce oral bone 
loss in our animal model remains unknown.  
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Figure 29.  Expression of immunologically silent, agonistic or antagonistic 
lipid A does not alter the ability of P. gingivalis to induce oral bone loss. 
Maxillae were dissected (n=8/group) 16 wk post-initial infection from ApoE-/- mice 
and scanned on a micro CT 40 apparatus. Using AMIRA software, three-
dimensional images were generated from micro-CT scans and were used to 
quantify oral bone loss (E). Representative two-dimensional images from (A) 
sham-infected mouse indicating no bone loss (B) P. gingivalis wild-type strain 
381 induced bone loss (C) PG1587381 and (D) PG1773381. Two-tailed unpaired t-
tests;  ***p<.001.   
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Chapter Summary  
By infecting atherosclerotic prone ApoE-/- mice with wild-type P. gingivalis and 
lipid A mutants, we were able to investigate the role of P. gingivalis lipid A 
expression on chronic inflammation at sites that were both local (oral cavity) and 
distant (vasculature) from infection. We revealed that expression of agonist lipid 
A by P. gingivalis (PG1587381) results in decreased vascular inflammation in the 
innominate artery as compared to wild-type P. gingivalis and the TLR4 antagonist 
strain PG1773381. Decreased vascular inflammation was characterized by 
decreased plaque accumulation and influx of macrophages. Furthermore, this 
phenotype correlated with a decrease in plaque accumulation in the entire aorta. 
Interestingly, P. gingivalis expression of agonist lipid A resulted in an induction of 
oral bone loss that was comparable to P. gingivalis expressing antagonist 
(PG1773381) or non-activating lipid A (wild-type 381). Collectively, these results 
indicate that expression of P. gingivalis lipid A structures that fail to engage TLR4 
or function as TLR4 antagonists enables P. gingivalis to evade host innate 
immune detection and contributes to inflammation at sites distant from infection. 
Furthermore, expression of lipid A does not play a role in the ability of P. 
gingivalis to induce inflammatory bone loss, indicating distinct mechanisms for 
the induction of local versus systemic inflammation by this pathogen.   
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Chapter 6. Suppression of autophagy in macrophages promotes bacterial 
survival independent of TLR signaling  
Studies from our group, and others, have reported that P. gingivalis is capable of 
surviving within host cells (Dorn et al.,2001; Wang et al.,2007; Wang and 
Hajishengallis, 2008; Reyes et al.,2013a; Maekawa et al.,2014; Slocum et 
al.,2014). However, the host cell signaling pathways and / or virulence factors 
expressed by P. gingivalis that promote pathogen survival remain undefined. Our 
results thus far indicate that P. gingivalis expression of antagonist lipid A enables 
this organism to survive within macrophages, suggesting that the ability of P. 
gingivalis to evade TLR4 signaling serves as a mechanisms for survival in 
macrophages. In addition to TLR4 evasion, TLR2 signaling has also been 
reported to be essential in P. gingivalis survival in macrophages (Wang et 
al.,2007). Furthermore, it has been shown that P. gingivalis enters macrophage 
lipid rafts, which may be a potential mechanism for P. gingivalis to evade 
degradation by the lysosomal pathway (Wang and Hajishengallis, 2008). In the 
case of L. pneumophila, this pathogen has been shown to utilize a raft-
dependent pathway to reach an autophagosome-lysosomal compartment for 
survival (Amer and Swanson, 2005). Other bacterial species have been shown to 
either infiltrate or evade entry into autophagosomes in order to avoid host 
clearance (Dorn et al.,2002; Colombo, 2005; Yuk et al.,2012; Cemma and 
Brumell, 2013). Whether P. gingivalis traffics to autophagosomes for bacterial 
survival and the role of TLRs in this process remains unknown.  
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Of note, LPS engagement of TLR4 has been reported to activate autophagy in 
macrophages (Xu et al.,2007; Wang et al.,2013). We propose the ability of P. 
gingivalis to modify its lipid A to a less immunostimulatory form contributes to 
autophagy evasion and bacterial survival, making the balance between TLR4 
evasion and TLR2 recognition essential to P. gingivalis bacterial survival. In this 
section we utilized BMDM from TLR2 and TLR4 deficient mice and the P. 
gingivalis lipid A mutant strains to determine the consequences of TLR2 signaling 
/ TLR4 evasion on bacterial survival and modulation of the autophagy pathway.  
 
Role of TLRs on P. gingivalis intracellular survival in macrophages  
Although we revealed that P. gingivalis expression of modified lipid A contributes 
to bacterial survival, the role of TLR2 and -4 signaling in promoting survival 
remain unknown. Therefore, we stimulated BMDM from TLR2 and -4 deficient 
mice with wild-type 381 and the lipid A mutants. Stimulation of BMDM from TLR2 
deficient mice with wild-type P. gingivalis or PG1773381 resulted in comparable 
levels of bacterial survival as compared to survival observed in wild-type BMDM 
(Figure 30).  These results were surprising due to previous reports that have 
documented a role for TLR2 signaling in P. gingivalis survival in the macrophage 
(Wang et al.,2007). Stimulation of BMDM deficient in TLR4 with wild-type P. 
gingivalis resulted in bacterial survival that was comparable to that observed in 
wild-type BMDM (Figure 30A).   Interestingly, stimulation of BMDM deficient in 
TLR4 with strain PG1773381 resulted in a decreased ability of this stain to survive, 
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suggesting that P. gingivalis antagonism of TLR4 may be important for this 
pathogen’s survival (Figure 30B).   Unfortunately, survival assays performed with 
strain PG1587381 resulted in an inability to recovery any viable CFUs from all 
mouse strains (n=2). Collectively, our results suggest that TLR2 signaling does 
not play a role in P. gingivalis survival in BMDM. However, P. gingivalis 
antagonistic activity at TLR4 may play a protective role in the ability of this 
pathogen to survive.   
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Figure 30. Role of TLR2 and -4 on P. gingivalis survival in macrophages. 
Bone marrow derived macrophages (BMDM) from wild-type (white bars), TLR2  
(grey bars) and TLR4 (black bars) deficient mice were stimulated with either P. 
gingivalis 381 (A) or PG1773 (B) for 2h and 6h.  Viable counts (CFU) of 
internalized P. gingivalis were determined by plating serial dilutions of 
macrophage lysates on blood agar plates. Graph depicts the mean + SEM of 
combined replicates from at least two independent experiments. %Viability 
Relative to Input indicates recovered intracellular CFU normalized to initial input 
(MOI 10 = 2X106 CFU/mL). *p<.05; NS indicates no significance; Two way 
ANOVA.  
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Role of TLR2 on P. gingivalis-mediated changes in autophagic activity  
Although we did not observe changes in survival in TLR2 deficient BMDM 
(Figure 31), we next sought to examine the role of P. gingivalis-mediated TLR2 
signaling on changes in autophagic activity. The autophagy protein, LC3 is a 
protein that exists on autophagosomes and therefore serves as a widely used 
marker for autophagy (Kabeya et al.,2000). Formation of autophagosomes 
involves the conjugation of phosphatidylethanolamine (PE) to LC3, which results 
in LC3 being converted from a soluble form (LC3-I) to the vesicle-associated 
form (LC3-II) (Sanjuan et al.,2009). Therefore, the amount of LC3 II usually 
correlates well with the number of autophagosomes (Mizushima et al.,2010) 
(Figure 31A). 
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Figure 31. Methods for monitoring autophagosome number and autophagic 
flux. Assessing autophagosome number relies on detecting the autophagosome 
marker, LC3 (A). The conversion of the cytosolic form of LC3 (LC3-I) to the 
membrane-bound lipidated form (LC3-II) can be determined by Western blot 
analysis (A-I). The number of autophagosomes can also be determined by 
utilizing cells that express GFP-LC3. Formation of autophagosomes results in 
GFP-LC3 puncta structures that can be counted by confocal microscopy (A-II). 
There are several techniques utilized for the assessment of autophagic flux (B). 
Degradation of autophagy-selective substrates, such as p62, can be determined 
by Western blot analysis (B-I). Detection of the GFP fragment by Western blot 
analysis, which is generated by the degradation of GFP-LC3 inside 
autolysosomes in cells expressing GFP-LC3, is another mechanisms for 
assessing autophagic flux (B-II). Finally, in LC3 turnover assays, degradation of 
LC3-II inside autolysosomes in the presence or absence of a lysosomal inhibitor 
can be determined by Western blot analysis (B-III). Figure modified from 
Mizushima et al 2010 (Mizushima et al.,2010). 
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By utilizing LC3 as a marker, we initially assessed autophagy induction in wild-
type BMDM stimulated with P. gingivalis from 15 to 180m by Western blot 
analysis. We observed a transient change in LC3 II levels, which began with a 
slight increase in LC3 II at 15m that decreased overtime (Figure 32A-B), 
suggesting that P. gingivalis induces changes in autophagosome number in 
macrophages. Western blot analysis of LC3 in TLR2 deficient cells demonstrated 
that there were no changes in LC3 levels between wild-type and TLR2 deficient 
BMDM at all time points (Figure 32A-B). These results indicate that the changes 
we observed in autophagosome number with P. gingivalis stimulation were not 
due to TLR2-dependent signaling.  
 
Autophagy is a dynamic pathway consisting of constitutive autophagosome 
synthesis / degradation; therefore, an increase in LC3 II levels may represent 
either an induction of autophagy, or alternatively, suppression of steps in the 
autophagic pathway that are downstream from autophagosome formation 
(Mizushima et al.,2010). For this reason, different methods for assessing 
autophagy are used in concert in order to distinguish autophagy induction from 
autophagy suppression (Figure 31). The term “autophagic flux” is used to denote 
this dynamic process.  
 
One method for determining autophagic flux is assessing the levels of other 
autophagy substrates, besides LC3. One of the best examples is p62 (Figure 
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31B-I). p62 becomes directly incorporated into autophagosomes after 
recognizing ubiquinitated cargo in the cytosol (Pankiv et al.,2007). Therefore, p62 
is efficiently degraded by autophagy and total levels of p62 inversely correlate 
with autophagy activity. We determined p62 levels in BMDM with P. gingivalis 
stimulation from 15 to 180m and observed an accumulation of p62 at 180m, 
suggesting that P. gingivalis decreases / suppresses autophagy at this time point 
(Figure 32A-C). We further immunoblotted for p62 in TLR2 deficient BMDM and 
observed that at 15m there is a slight increase in p62 in TLR2 deficient cells 
compared to wild-type cells, suggesting that TLR2 signaling may play a minor 
role in the initial induction of autophagy at this timepoint. At both 60 and 180m we 
did not observe any changes in p62 levels in wild-type BMDM versus TLR2 
deficient BMDM (Figure 32A-C). These results further confirm that TLR2 
signaling is likely to play no role, or a very minor role, in P. gingivalis-mediated 
changes in autophagic flux in the macrophage.  
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Figure 32. TLR2 plays a minor role in autophagic induction in macrophages 
stimulated with P. gingivalis. (A) BMDM from wild type and TLR2 deficient 
mice were stimulated with P. gingivalis at an MOI of 10 and cell lysates were 
collected at 15, 60 and 180m after infection. LC3 and p62 levels were detected 
by Western blot analysis.  Graphs represent mean densitometry for LC3 (B) or 
p62 (C) of replicate samples from two independent mechanisms. Wild type 
BMDM (solid line), TLR2-/- BMDM (dotted line). *p<.05; Two-way ANOVA 
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Role of P. gingivalis lipid A expression on changes in autophagic activity  
Since P. gingivalis has evolved mechanisms to evade / antagonize TLR4 
activation, we utilized the lipid A mutants in order to assess the role of P. 
gingivalis-mediated TLR4 signaling on autophagy induction / suppression in 
macrophages. We first assessed levels of LC3, and observed an initial increase 
in LC3 II, which decreased over time when cells were stimulated with the TLR4 
agonist strain PG1587381 and the TLR4 antagonist strain PG1773381 (Figure 
33B-D). These results are comparable to what we observed with wild-type P. 
gingivalis (Figure 33A, D).  
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Figure 33. P. gingivalis expression of lipid A does not contribute to the 
induction of autophagosomes in macrophages. BMDM were stimulated with 
wild-type P. gingivalis (A) or the lipid A mutant strains PG1587381 (B) and 
PG1773381 (C) at an MOI of 10 and cell lysates were collected 15, 30, 60 and 
90m after infection.  Levels of LC3 were detected by Western blot analysis. 
Unstim indicates media control. As a positive control, cells were stimulated with 
bafiolomycin (BAF 100ng/mL) for 2h. DMSO serves as the vehicle control. (D) 
Graph represents densitometry analysis of LC3 II levels compared to β-actin. 
Bars indicate mean + SEM. Data represents at least three independent 
experiments. Wild-type 381 (solid line); PG1587381 (Dashed line); PG1773381 
(Dotted line).  
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We next assessed levels of p62, and observed an accumulation of p62 at 180’ 
when cells were stimulated with both PG1587381 and PG1773381, which is 
comparable to the results we observed with wild-type P. gingivalis (Figure 34).  
  
 
160 
  
 
161 
Figure 34. P. gingivalis lipid A expression does not contribute to the 
accumulation of p62 at 3h in macrophages. BMDM were stimulated with wild-
type P. gingivalis (A) or the lipid A mutant strains PG1587381 (B) and PG1773381 
(C) at an MOI of 10 and cell lysates were collected 15, 30, 60, 90 and 180m after 
infection.  Levels of p62 were detected by Western blot analysis. Unstim 
indicates media control. As a positive control, cells were stimulated with 
bafiolomycin (BAF 100ng/mL) for 2h. (D) Graph represents densitometry analysis 
of p62 compared to β-actin. Bars indicate mean + SEM. Data represents at least 
two independent experiments. Wild-type 381 (solid); PG1587381 (Dashed line); 
PG1773381 (Dotted line).  
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To further confirm these results we performed an additional assay for autophagic 
flux. In this experiment we utilized immortalized macrophages that stably express 
GFP-LC3 (Mizushima et al.,2010; Harris et al.,2011). Although GFP fluorescence 
is quenched in the lysosome, due to the acidic environment, GFP is still 
detectable by Western blot analysis. Therefore, the detection of a free GFP 
fragment compared to intact GFP-LC3 is a way to assess autophagosome 
turnover, since free GFP will be generated from the degradation of GFP-LC3 in 
the autolysosome (Figure 31B-II). We stimulated immortalized macrophages that 
stably express GFP-LC3 with wild-type P. gingivalis and the lipid A mutants at 
15, 30, 60 90 and 180m and observed an initial increase in the ratio of cleaved 
GFP over intact GFP-LC3, followed by a decrease in cleavage overtime (Figure 
35). These results correlate well with our other results where we observed an 
initial increase in autophagic activity followed by a decrease / suppression of 
autophagy at 3h. Since the results we observed with the lipid A mutants are 
comparable to what we observed with wild-type 381, it is likely that lipid A 
expression does not contribute to P. gingivalis mediated changes in autophagic 
activity in macrophages.  
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Figure 35.  P. gingivalis lipid A expression does not contribute to changes 
in autophagic flux in mouse macrophages. Immortalized macrophages 
(iBMM) stably overexpressing GFP-LC3 were stimulated with wild-type P. 
gingivalis 381 (A) or the lipid A mutant strains PG1587381 (B) and PG1773381 (C). 
Cell lysates were collected and intact GFP-LC3 (high molecular weight) and GFP 
(low molecular weight) were detected with a GFP antibody by Western blot 
analysis. Rapamycin (10ug/mL) and 3-MA (3mM) serve as positive and negative 
controls respectively. (D) Graph represent mean densitometry of the ratio of 
cleaved GFP over intact GFP-LC3 from at least three independent experiments. 
Wild-type 381 (Solid line); PG1587381 (Dashed line); PG1773381 (Dotted line).  
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Additional assays to confirm P. gingivalis modulation of autophagic 
activity in macrophages  
Due to the dynamic nature of autophagy, multiple experiments are usually 
performed to elucidate changes in autophagic flux by a given stimulus (Figure 
31) (Mizushima et al.,2010). Thus far we have determined that P. gingivalis 
induces an initial increase in autophagic activity that is followed by a decrease / 
suppression of activity at later timepoints. To confirm the initial increase in 
autophagy we observed with P. gingivalis stimulation, we assessed 
autophagosomes number in iBMM-GFP LC3 cells by confocal microscopy 
(Figure 31A-II). As mentioned previously, upon induction of autophagosome 
formation LC3 is lipidated and recruited to autophagosome membranes. This 
specific recruitment to autophagic membranes is associated with a shift from a 
diffuse cytosolic staining to a punctuate pattern (Sanjuan et al.,2009). Generally, 
the number of GFP-LC3 punctae is an accurate measure of autophagosome 
number. Thus, autophagosomes can be quantified by identification of these 
punctae structures (Figure 36A). We counted the number of punctae per cell and 
reported the average for every condition (Figure 36B). Stimulation of cells with 
media alone (unstimulated), resulted in an average of 9 punctae / cell. This result 
represents the number of autophagosomes that are present under basal 
autophagy conditions. Therefore, we next set a threshold of more than 10 
autophagosomes / cell in order to effectively distinguish cells that are “autophagy 
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active” verses “autophagy inactive” and reported the results as a “percentage of 
cells with more than 10 punctae” (Mizushima et al.,2010) 
.   
Stimulation of iBMM-GFP LC3 with P. gingivalis at 15 and 60m, although not 
statistically significant, resulted in an increased trend in autophagosome number 
from 15 to 60m (Figure 36C). Interestingly, these results were slightly different 
from the results observed in primary BMDM assessing LC3 levels by Western 
blot analysis. In primary cells, we observed an increase in autophagosome 
formation at 15m, which decreased over 90m.  In immortalized macrophages, we 
observed an increase in autophagosome formation at 60m. These differences 
could simply be due to different kinetics for autophagosome formation in an 
immortalized cell line versus primary cells and also a difference in the technique: 
immunoblotting versus confocal imaging.  
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Figure 36. P. gingivalis increases autophagosome number in mouse 
macrophages at 60m. (A) Immortalized macrophages that stably express GFP-
LC3 were stimulated with P. gingivalis at an MOI of 10 for either 15 or 60m. GFP-
LC3 punctae were observed by confocal microscopy. (B) Average number of 
punctae / cell were counted for each condition from 100 cells. (C) A threshold of 
more than 10 autophagosomes / cell was set in order to distinguish cells that 
were “autophagy active” versus “autophagy inactive.” The graph depicts the 
number of cells with more than 10 autophagosomes / cell and is calculated as a 
percentage from total cells counted. Bars indicate mean +/- SEM from two 
independent experiments. Rapa indicates rapamycin treatment (10ug/mL) and 
served as the positive control. NS indicates not statistically significant; One way 
ANOVA.  
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In order to determine if the changes in autophagosome number we observed 
were due to an increase in autophagosome formation versus a block in 
autophagosome degradation, we performed an LC3 turnover assay by utilizing 
the lysosomal inhibitor bafilomycin A1 (Figure 31B-III). When cells are treated 
with bafilomycin A1, the degradation of LC3 II is blocked, resulting in the 
accumulation of LC3 II (Tanida et al.,2008). Therefore, assessing the amount of 
LC3 II between samples in the presence or absences of lysosomal inhibitors 
allows for the measurement of autophagosome formation versus degradation 
(Mizushima et al.,2010). Utilizing primary macrophages, at 15m we observed 
LC3 II levels that were greater in the presence of bafilomycin and P. gingivalis 
compared to bafilomycin alone, suggesting that the observed levels of increased 
LC3 II at 15m is due to increased formation of autophagic vesicles, and therefore 
autophagy initiation (Figure 37A-B). However, at 180m we observed decreased 
levels in LC3 II compared to bafilomycin alone, suggesting P. gingivalis interferes 
with the functions of bafilomycin and suppresses autophagy at this time point 
(Figure 37C-D).  
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Figure 37. P. gingivalis induces an initial increase then decrease in 
autophagosome formation in mouse macrophages. BMDM were pretreated 
with bafilomycin (Baf 100ng/mL) for 2hr and then stimulated with wild-type 381 at 
an MOI of 10 for either 15m (A-B) or 180m (C-D). Levels of LC3 were detected 
by Western blot analysis (A,C). Graphs represent densitometry analysis of LC3 
expression compared to β-actin from three independent experiments (B,D). Bars 
indicate mean + SEM. *p<.05; Student’s unpaired t-test.  
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Suppression of autophagy correlates with bacterial survival  
 
A number of pathogens that intercept the autophagic pathway do so in order to 
promote their intracellular survival (Colombo, 2005; Yuk et al.,2012; Cemma and 
Brumell, 2013; Choy and Roy, 2013).  Therefore, we next sought to investigate 
the correlation between P. gingivalis suppression of autophagy at 3h and the 
ability of the bacterium to survive within the macrophage. We stimulated BMDM 
with wild-type P. gingivalis for 15, 30, 60, 90 and 180m and performed an 
antibiotic protection assay in order to determine survival at these timepoints.. We 
observed a significant recovery of viable bacteria at 180m, compared to all other 
time points (Figure 38).  Notably, at 180m we have observed P. gingivalis 
decreases autophagic activity. Our results suggest that P. gingivalis inhibition of 
autophagic activity at 180m may promote bacterial survival within macrophages 
at this timepoint.   
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Figure 38. P. gingivalis intracellular survival significantly increases at three 
hours post stimulation of macrophages. BMDM were stimulated with P. 
gingivalis MOI 10 at the indicated time points. Viable counts (CFU) of internalized 
P. gingivalis were determined by plating serial dilutions of macrophage lysates on 
blood agar plates. Bars indicate mean + SEM from triplicate wells and represents 
two independent experiments. ***p<.001 One way ANOVA with Bonferroni post 
test.  
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Due to the difficulty of performing targeted gene deletions in monocytic cells, we 
chose to utilize inhibitors of the autophagic pathway in order to determine how 
inhibition of autophagy would impact P. gingivalis survival in the macrophage.  
Although mTOR is a master regulator of autophagy activation, class III 
phosphatidylinositol-3-OH kinases (PI3K) and the phosphotidylinositol-3 
phosphate that they produce are also essential for starvation induced autophagic 
signaling and autophagosome formation (Kirkegaard et al.). Therefore, many 
commonly used inhibitors of autophagy target cellular PI3Ks.  
 
We pretreated BMDM with the PI3K inhibitor, LY294002, and then subsequently 
stimulated cells with P. gingivalis for either 1h or 3h. We observed an increase in 
bacterial CFUs at the 3h time point, which was dose dependent (Figure 39). 
Interestingly, our results are in contrast to other studies that have assessed P. 
gingivalis survival in the presence of PI3K inhibitors. Studies reporting the use of 
LY294002 at comparable concentrations in neutrophils (Maekawa et al.,2014), 
and another PI3K inhibitor wortmannin (Dorn et al.,2001), in HAEC, resulted in a 
decreased ability of P. gingivalis to survive when the activity of PI3K was 
blocked. 
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Figure 39. Inhibition of PI3K enhances P. gingivalis survival in 
macrophages. (A) Bone marrow derived macrophages (BMDM) were stimulated 
with P. gingivalis for 1h or 3h in the presence (black bars) or absence (white 
bars) of pretreatment with the PI3K inhibitor LY294002 (20uM) for 1h. Gray bars 
indicate DMSO vehicle control. Viable counts (CFU) of internalized P. gingivalis 
were determined by plating serial dilutions of macrophage lysates on blood agar 
plates. % Viability Relative to Input indicates recovered intracellular CFU 
normalized to initial input (MOI 10 = 2X106 CFU/mL). (B) Intracellular P. 
gingivalis CFUs were determined at 3h in the presence (inhibitor) or absence 
(vehicle) of increasing doses of LY294002: 2uM (white bars), 20uM (gray bars) or 
200uM (black bars). Graphs depict the mean + SEM of combined replicates from 
one experiment. *p<.05; **p<.01; ***p<.001; Two-way ANOVA with Bonferroni 
post test.  
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We next utilized bafilomycin to target the autophagic pathway that involves 
autophagosome / lysosome fusion. We pretreated BMDM with bafilomycin then 
stimulated with P. gingivalis for either 1h or 3h. We observed a significant 
increase in recovery of viable bacteria at the 3h time point (Figure 40A). These 
results suggest that P. gingivalis does not utilize an acidic environment for 
survival, like other pathogens such as S. Typhimurium (Rathman et al.,1996), B. 
bronchiseptica (Schneider et al.,2000), C. burnetii (Heinzen et al.,1996) and B. 
abortus (Starr et al.,2008). Of note, recovery of P. gingivalis with bafilomycin 
treatment was only significant at 3h, suggesting that at 3h P. gingivalis 
suppression of autophagy facilitates bacterial recovery, but not to the same 
extent as the inhibitor alone. We next performed this assay in reverse, by 
stimulating first with P. gingivalis at 3h, and then subsequently added in 
bafilomycin over a time course from 1h to 3h. We observed similar results as 
pretreatment with bafilomycin, where P. gingivalis was able to survive better in 
the presence of the inhibitor (Figure 40B). Interestingly, the time dependent 
increase of the inhibitor did not increase the viability of P. gingivalis. These 
results suggest that although inhibition of acidification increases bacterial 
survival, changing the time when for when bafilomycin is added does not affect 
this result. Furthermore, P. gingivalis does not utilize an acidic environment for 
survival.  
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Figure 40. Inhibition of lysosomal acidification enhances P. gingivalis 
survival in macrophages. (A) Bone marrow derived macrophages (BMDM) 
were pretreated with the lyosomal inhibitor bafilomycin (BAF, 100ng/mL) for 2hr 
then stimulated with P. gingivalis for 1h (white bars) or 3h (black bars). Untreated 
indicates no BAF treatment. Viable counts (CFU) of internalized P. gingivalis 
were determined by plating serial dilutions of macrophage lysates on blood agar 
plates. Graph depict the mean + SEM of combined replicates from two 
independent experiments. %Viability Relative to Input indicates recovered 
intracellular CFU normalized to initial input (MOI 10 = 2X106 CFU/mL). (B) 
Intracellular P. gingivalis CFUs were determined after stimulating BMDM with P. 
gingivalis for 3h (stripped bar) in the presence or absence of bafilomycin for 1h 
(4h total; white bars), 2h (5h total; grey bars), and 3h (Total 6h; black bars). 
**p<.01; ***p<.001; Two way ANOVA. NS indicates No Significance.  
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It is important to note that results with the use of inhibitors should be interpreted 
very carefully due to the pleiotropic effects of these compounds (Yang et 
al.,2013; Kirkegaard et al.). Furthermore, it is suggested that results with 
inhibitors need to be confirmed in autophagy deficient cells (Mizushima et 
al.,2010). A number of studies reporting on autophagy deficiency utilize mouse 
embryonic fibroblasts (MEFs), deficient in Atg5, the autophagy protein that is 
essential for autophagosome formation (Zhao et al.,2007; 2008; Moreau et 
al.,2010). MEFs are frequently used because a global deletion of Atg5 in mice is 
embryonic lethal (Zhao et al.,2008). There are a few studies that have utilized 
macrophages deficient in Atg5, however these macrophages were cultured from 
the bone marrow of Atg5 fl/fl mice, which have a specific deletion of Atg5 in the 
myeloid lineage (Dupont et al.,2011). Due to the limited availability of these mice, 
we searched for other mouse models utilized in autophagy studies and found 
mice deficient in LC3β.  Murine LC3 is present in two isoforms, α and β (humans 
have an additional isoform, γ). The LC3 knockout was made using the β isoform 
due to its higher abundance of the two isoforms (Cann et al.,2007).   
 
We assessed P. gingivalis survival in BMDM from LC3β deficient mice and 
observed a slight decrease in bacterial recovery from LC3β-/- BMDM at 1h, but 
observed no differences in survival at 3h (Figure 41A). To confirm these results 
were due to a loss of LC3β, we immunoblotted for LC3β in wild type and LC3β 
deficient BMDM stimulated with P. gingivalis for 1h and 3h.  Although we 
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observed a complete absence of LC3β at both timepoints (Figure 41B), these 
results do not confirm the absence of autophagosome formation.  Cann et 
al.have shown in vitro that autophagosomes form normally under autophagy 
induction in LC3β-/- MEFs (Cann et al.,2007), suggesting compensatory 
mechanisms for autophagosome formation in the absence of LC3β. Therefore, 
future studies should be performed utilizing BMDM from Atg5 fl/fl mice to confirm 
these results, since loss of Atg5 in MEFs has provided clear evidence of impaired 
starvation induced autophagy (Cann et al.,2007).  Furthermore, BMDM from Atg5 
fl/fl mice have been previously characterized for their loss of autophagy (Dupont 
et al.,2011).  
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Figure 41. Deletion of LC3β slightly contributes to P. gingivalis intracellular 
survival at 1h. (A) BMDM from wild type (white bars) and LC3β deficient mice 
(black bars) were stimulated with P. gingivalis for 60’ or 180’ and viable counts 
(CFU) of internalized P. gingivalis were determined by plating serial dilutions of 
macrophage lysates on blood agar plates. Graph depict the mean + SEM of 
combined replicates from one experiment. %Viability Relative to Input indicates 
recovered intracellular CFU normalized to initial input (MOI 10 = 2X106 CFU/mL). 
(B) Levels of LC3 were detected in lysates from wild-type and LC3β deficient 
BMDM by Western blot analysis. Unstim indicates cells treated with media alone. 
*p<.05; Two way ANOVA. NS indicates no significance.  
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Chapter Summary  
In this chapter we assessed the role of P. gingivalis on autophagic activity in 
macrophages and how this relates to the bacterial survival. We observed that P. 
gingivalis induces a very early (between 15 to 60m) induction of autophagy in 
macrophages followed by suppression of autophagic activity by 180m. This 
suppression of autophagic activity correlated with increased survival of P. 
gingivalis at this time point. Substantial suppression of autophagy, by utilizing the 
lysosomal acidification inhibitor bafilomycin, resulted in even greater survival of 
P. gingivalis. These results suggests that P. gingivalis is able to suppress 
autophagy, however not to the extent of utilizing an inhibitor. This suppression 
potentially prevents subsequent clearance of P. gingivalis by lysosomal 
degradation.  
 
We further investigated the role of TLR2 signaling and P. gingilvais lipid A 
expression on the ability of P. gingivalis to induce / suppress autophagic activity 
in macrophages. We did not observe a major role for TLR2 in modulating 
autophagic activity in macrophages stimulated with P. gingivalis. Furthermore, 
we did not observe a role for TLR2 signaling in P. gingivalis survival. However, 
we did observe P. gingivalis antagonism of TLR4 promotes bacterial survival. 
These results correlate well with our previous finding that strain PG1773381, 
expressing antagonist lipid A, was able to survive better than wild-type 381 in 
macrophages (Chapter 5). Collectively, the results from this chapter suggest that 
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P. gingivalis modulation of the autophagic pathway in macrophages is not 
dependent on TLR2 signaling or expression of lipid A. P. gingivalis survival 
appears to depend on suppression of autophagy and antagonism of TLR4. 
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Chapter 7. Discussion  
In this study we utilized genetically defined strains of P. gingivalis, which equally 
activate TLR2, but function exclusively as agonist, antagonist or non-activating at 
TLR4 to define the role of TLR4 evasion on host innate immune activation and 
chronic inflammation. We determined that expression of TLR4 antagonist lipid A 
was associated with the induction of low levels of proinflammatory mediators 
(Figure 42A), failed activation of the inflammasome and increased bacterial 
survival in macrophages (Figure 42B). Oral infection of ApoE-/- mice with the P. 
gingivalis strain expressing antagonistic lipid A (PG1773381) resulted in vascular 
inflammation, macrophage accumulation and atherosclerosis progression 
(Figure 42D). In contrast, a P. gingivalis strain producing exclusively agonistic 
lipid A (PG1587381) augmented levels of proinflammatory mediators (Figure 42A) 
and activated the inflammasome in a caspase-11-dependent manner (Figure 
42B). These results correlated with host cell lysis and decreased bacterial 
survival. ApoE-/- mice infected with this strain exhibited diminished vascular 
inflammation, macrophage accumulation, and atherosclerosis progression 
(Figure 42D). Notably, the ability of P. gingivalis to induce local inflammatory 
bone loss was independent of lipid A expression, indicative of distinct 
mechanisms for induction of local versus systemic inflammation by this pathogen 
(Figure 42D).  
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Although we revealed expression of antagonist / non-activating lipid A resulted in 
increased bacterial survival, the underlying mechanisms remained elusive. A 
number of pathogens that evade host clearance enter the autophagic pathway. 
We demonstrated that P. gingivalis initially increased autophagic activity very 
early (from 15-60m) but subsequently suppressed autophagy at later timepoints 
(3h). The ability of P. gingivalis to modulate autophagic activity was independent 
of lipid A expression while TLR2 signaling played a minor role. Suppression of 
autophagy by P. gingivalis at 3h was associated with an accumulation of p62 
suggesting a block in degradation of autophagosomes (Figure 42C). 
Interestingly, at this time point (3h) we observed significant bacterial survival 
(Figure 42C). Collectively, our results indicate that P. gingivalis evades innate 
immunity via expression of antagonist lipid A and suppression of autophagy, 
which in part is associated with site-specific vascular inflammation.  
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Figure 42. P. gingivalis exploitation of host innate immune defenses in the 
macrophage and induction of site-specific chronic inflammation.  (A) The 
unique ability of P. gingivalis to signal through TLR2 yet evade TLR4 results in 
attenuated production of the proinflammatory mediators IL-6 and IL-8 and 
enhanced levels of TNFα. (B) Expression of underacylated lipid A moieties 
contributes to evasion of caspase-11 activation and subsequent attenuation of 
host cell lysis and IL-1α release. Failure to activate caspase-11 prevents 
caspase-1 activation, resulting in low levels of IL-1β release. (C) By currently 
unknown mechanisms, P. gingivalis induces an accumulation of p62 in 
macrophages, suggesting a block in autophagosome / lysosomal fusion. This 
event correlated with enhanced bacterial survival.  (D) P. gingivalis expression of 
antagonist lipid A had no affect on inflammatory oral bone loss, but was 
associated with enhanced systemic inflammation in the vasculature.   
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Role of antagonist lipid A on immune evasion  
We and others have reported that the expression of P. gingivalis lipid A is 
regulated by growth phase, temperature, and levels of hemin (Al-Qutub et 
al.,2006; Coats et al.,2009a; Curtis et al.,2011). During growth under hemin-
replete conditions, P. gingivalis expresses an antagonistic lipid A, due to the 
repression of 1-phosphatase activity (Coats et al.,2009a). In vitro studies have 
documented that the antagonist lipid A expressed by P. gingivalis antagonizes E. 
coli LPS binding to TLR4 (Coats et al.,2007) and dampens cytokine responses 
typically induced by other Gram-negative pathogens (Bostanci et al.,2007). 
Therefore, these reports, among others have proposed P. gingivalis lipid A 
modifications as an important mechanism utilized by P. gingivalis for evasion of 
TLR4 signaling (Coats et al.,2009a; 2011; Herath et al.,2013).  However, it is 
important to note that these studies utilized purified P. gingivalis LPS in an in 
vitro setting. Our study revealed that purified LPS resulted in discrepancies in 
TLR4 activation by isolated LPS versus the whole bacterium. These differences 
observed in the host response may be a reflection of LPS structure and 
composition on the cell surface, which leave us with new areas of investigation 
with regards to LPS translocation. Potentially, the less potent lipid A forms (m/z 
1368, 1448, 1688) may be primarily expressed on the bacterial outer membrane 
and, consequently, render wild-type 381 and PG1773381 unable to activate TLR4. 
In contrast, strain PG1587381 is expected to exclusively accumulate lipid A TLR4 
agonists (m/z 1688 and possibly m/z 1768) in the outer membrane since the 
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presence of a lipid A 4’-phosphate precludes production of the lipid A antagonist 
(m/z 1448) or non-activating lipid A (m/z 1368) in this strain.  These findings point 
to the significance of utilizing the whole bacterium, versus purified ligands, in 
understanding the role of P. gingivalis LPS on innate immune signaling and 
chronic inflammation.  
 
Antagonist lipid A contributes to evasion of the inflammasome   
An important observation from this study was that P. gingivalis failed to activate 
the inflammasome. It has recently been reported that Gram-negative bacteria 
activate a non-canonical inflammasome pathway that is mediated by caspase-11 
(Kayagaki et al.,2011; Broz et al.,2012; Rathinam et al.,2012). Kayagaki et 
al.(Kayagaki et al.,2013) have shown that H. pylori, whose tetra-acylated lipid A 
poorly activates the TLR4 complex, failed to trigger the non-canoncial 
inflammasome. Although TLR4 signaling correlates with non-canonical 
inflammasome activity, this group reported that activation of the non-canonical 
inflammasome is independent of TLR4 signaling, further suggesting an unknown 
sensor in the cytosol that detects modified lipid A. It has recently been suggested 
that the unknown sensor may actually be caspase-11 due to a report by Shi et 
al., that demonstrated that caspase-11 is able to directly detect lipid A in the 
cytosol (Shi et al.,2014). We found that caspase-11 expression was essential for 
IL-1β production elicited by P. gingivalis strain PG1587381, pointing to a pivotal 
role for activation of the non-canonical inflammasome in P. gingivalis infection.  
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Pathogen evasion of inflammasome activation has been proposed to serve a 
dual role: to prevent IL-1β release and to circumvent host cell death in order to 
provide an intracellular niche for the pathogen to survive (Shimada et al.,2012). 
Indeed, we observed that the low levels of IL-1β induced by P. gingivalis strains 
381 and PG1773381 correlated with an enhanced ability of these organisms to 
survive in macrophages. Likewise, the induction of relatively high levels of IL-1β 
by P. gingivalis strain PG1587381 correlated with decreased survival of this strain 
in macrophages. The enhanced survival we observed with wild-type 381 and 
PG1773381 are in agreement with our observation that both strains were relatively 
resistant to killing in the presence of the cationic antimicrobial peptide polymyxin 
B. In contrast, strain PG1587381 was unable to survive intracellularly and was 
rapidly killed. These results suggest that P. gingivalis utilizes multiple 
mechanisms concurrently to promote its adaptive fitness.   
 
Role of antagonist lipid A on site-specific inflammation 
To date, only this study and a study by the Darveau laboratory in a rabbit model 
of periodontitis (Zenobia et al.,2014) have begun to shed light on the 
immunological consequences of differential activation of the TLR4 complex by P. 
gingivalis LPS through the use of live bacteria that express a “locked” lipid A 
profile that is not responsive to growth conditions. In this study, we assessed the 
host response in the oral cavity and vasculature, physiologically relevant sites of 
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chronic inflammation observed in humans. Therefore, for the first time, the role of 
antagonistic lipid A (typically expressed under hemin-replete conditions) in the 
induction of chronic inflammation, at both local and distant sites from infection 
could be investigated.  We observed that P. gingivalis strains 381 and PG1773381 
induced comparable levels of inflammatory atherosclerosis suggesting that in 
vivo P. gingivalis is exposed to a hemin-replete environment and predominantly 
expresses an antagonistic lipid A that exacerbates chronic systemic 
inflammation.  
 
Our results were in agreement with recent studies documenting a role for lipid A 
modifications on the ability of a number of other highly pathogenic Gram-negative 
pathogens to elicit disease (Miller et al.,2005; Needham and Trent, 2013). For 
example, F. novicida expresses a tetra-acylated lipid A, with one phosphate 
group and does not induce a TLR4 response (Hajjar et al.,2006). Y. pestis 
expresses a tetra-acylated lipid A that functions as a TLR4 antagonist at 37oC, 
which allows this pathogen to remain undetected in the bloodstream during early 
stages of infection (Kawahara et al.,2002; Rebeil et al.,2006).  Generation of a 
strain of Y. pestis that expressed a more immunostimulatory LPS conferred a 
protective immune response against this pathogen (Montminy et al.,2006). 
Likewise, Pseudomonas aeruginosa expresses a modified LPS which promotes 
evasion of TLR4 signaling, favors intracellular survival, and has been postulated 
to contribute to chronic persistence in cystic fibrosis patients (Cigana et al.,2009). 
  
 
195 
In agreement with these studies, we have shown that P. gingivalis modifies its 
lipid A structure in order to evade host defenses and establish chronic infection 
leading to persistent low-grade inflammation in the vasculature. Analogous to the 
study that utilized a strain of Y. pestis with a more immunostimulatory LPS, our 
use of a P. gingivalis strain with a more immunostimulatory LPS  (PG1587381) 
conferred protection to systemic inflammation in the vasculature. However, unlike 
other Gram-negative species that modify their lipid A, P. gingivalis evasion of 
host innate immunity at TLR4 results in progression of disease at a site that is 
distant from local infection by gaining access to the vasculature.  Furthermore, 
the antagonist lipid A expressed by P. gingivalis can actively antagonize binding 
and cytokine responses induced by other Gram-negative organisms (Bostanci et 
al.,2007; Coats et al.,2007).  
 
An interesting finding from this study was expression of P. gingivalis modified 
lipid A species did not alter the ability of the organism to induce oral inflammatory 
bone loss. These results are in agreement with previous studies that show that 
TLR4 is not needed for the induction of inflammatory bone loss, and it is 
predominantly mediated via TLR2 signaling (Burns et al.,2006; Gibson and 
Genco, 2007; Ukai et al.,2008; Hayashi et al.,2010b). We also recently identified 
a TLR2- and TNF-dependent macrophage-specific mechanism for P. gingivalis-
induced inflammatory bone loss in vivo (Papadopoulos et al.,2013). In the current 
study, we observed comparable levels of TNFα were induced in macrophages 
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stimulated with wild-type 381 and the lipid A mutants.  In addition to the role of 
TNFα, it has been recently reported that P. gingivalis is able to induce oral bone 
loss at very low colonization levels, which triggers changes to the amount and 
composition of the oral commensal microbiota (Hajishengallis et al.,2011). We 
have recently demonstrated in a rabbit model of periodontitis that lipid A 
phosphatases are required for both colonization of the rabbit and increases in the 
oral microbial load (Zenobia et al.,2014). Whether this same mechanism for 
inflammatory bone loss is at play in our study remains to be determined, however 
is currently being investigated in the Darveau laboratory (University of 
Washington, Seattle, WA) by utilizing gingival tissue extracted from the ApoE-/- 
mice from this study infected with wild-type 381 and the lipid A mutants.  
 
P. gingivalis intracellular survival and systemic dissemination 
It is thought that survival and replication inside macrophages represents an 
important step in early stages of infection for evading the immune response and 
enabling bacterial dissemination (Pujol and Bliska, 2005; Moreau et al.,2010). 
Therefore, we proposed that P. gingivalis entry and survival within myeloid cells 
might be a mechanism for dissemination of this bacterium from the oral cavity to 
other systemic sites, such as the vasculature. We recently identified P. gingivalis 
in blood myeloid dendritic cells of humans with chronic periodontitis, suggesting a 
role for blood myeloid dendritic cells in harboring and disseminating pathogens 
from the oral mucosa to atherosclerotic plaques (Carrion et al.,2012). 
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Furthermore, we reported that P. gingivalis utilizes its minor fimbriae to engage 
DC-SIGN in order to avoid autophagosome / lysosomal trafficking in human 
myeloid dentritic cells (El-Awady et al.,2015). In the neutrophil, P. gingivalis has 
been shown to interfere with the killing functions of this cell through mechanisms 
relying on crosstalk between complement receptor C5aR and TLR2 (Maekawa et 
al.,2014). In the macrophage, we have shown that expression of antagonist / 
non-activating lipid A contributes to bacterial survival. Wang et al.(Wang et 
al.,2007; Wang and Hajishengallis, 2008) have shown that intracellular survival of 
P. gingivalis in macrophages is dependent upon TLR2 signaling and entry into 
lipid rafts. Other reports have shown that pathogens that hijack lipid rafts do not 
readily fuse with late endosomes and lysosomes and have shown to fuse to 
autophagosomes (Simons and Gruenberg, 2000; Amer and Swanson, 2005). 
Whether P. gingivalis utilizes a similar mechanism for survival is unknown. To 
date, there is only one report that has indicated that P. gingivalis traffics to 
autophagosomes for survival, which was in human aortic endothelial cells (Dorn 
et al.,2001).  Therefore, in this study we attempted to address whether P. 
gingivalis exploits the autophagic pathway via TLR2 and evasion of TLR4 
signaling in order to promote its survival.  
 
Role of TLR / autophagy crosstalk on P. gingivalis survival  
In our study, we observed wild-type P. gingivalis survival in both TLR-2 and -4 
deficient BMDM was comparable to wild-type BMDM, which was surprising given 
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the previous reports by Wang et al (Wang et al.,2007). These differences could 
potentially be both bacterial strain and cell type dependent. Our study utilized P. 
gingivalis strain 381 and primary bone marrow derived macrophages, while 
Wang et al utilized P. gingivalis strain 33277 and peritoneal derived 
macrophages, which have been classically considered a more “activated” 
macrophage compared to primary, naïve BMDM.   
Interestingly, we observed a decreased ability of the TLR4 antagonist strain 
(PG1773381) to survive in TLR4 deficient BMDM compared to wild-type BMDM. 
We did not observe this result with wild-type P. gingivalis. This observation is 
likely due to the enhanced ability of PG1773381 to antagonize bactericidal 
functions of TLR4, since it expresses exclusively antagonist lipid A while wild-
type P. gingivalis expresses a mixture of agonist, antagonist and non-activating 
lipid A. These results help explain our previous reports where we observed 
enhanced survival in wild-type BMDM with PG1773381 compared to wild-type 
BMDM (Slocum et al.,2014). Collectively, our results indicate that P. gingivalis 
manipulates its interaction at TLR4 to enhance bacterial survival; an event that is 
independent of TLR2 signaling.  
In regards to TLR signaling on P. gingivalis-mediated changes in autophagic 
activity, we observed that TLR2 played a minor role on the initial induction of 
autophagy with P. gingivalis at 15m, as indicated by increased levels of p62 in 
TLR2 deficient versus wild-type BMDM at this timepoint. However we did not 
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observe a role for P. gingivalis-mediated TLR4 signaling on autophagic activity, 
which was determined by utilizing the lipid A mutants. Stimulation of wild-type 
BMDM with wild-type P. gingivalis and the TLR4 agonist and antagonist strains 
resulted in comparable levels of LC3 II induction at early time points (15m) and 
accumulation of p62 at later timepoints (3h). Utilizing iBMM-GFP LC3 we 
observed comparable ratios for GFP cleavage for all three strains from 15m to 
3h. These results with the lipid A mutant strains were surprising due to previous 
reports documenting LPS as a sensor for TLR4-mediated autophagy activation 
(Xu et al.,2007; Wang et al.,2013).  
A number of studies that have investigated the link between TLR signaling and 
autophagy have utilized TLR ligands rather than intact microbes (reviewed in 
(Delgado et al.,2008). Therefore, our results add to our currently very limited 
knowledge on pathogen directed TLR signaling and autophagy. It is not yet 
known if pathogens even possess strategies to block TLR dependent autophagy 
induction (Deretic and Levine, 2009). Some reports propose that activation of 
autophagy in an infected cell might represent a fairly conserved response 
triggered by PRRs that recognize microbe-specific PAMPs, and may not be a 
pathogen specific response (Deretic and Levine, 2009).  Therefore, the microbial 
adaptations to suppress autophagy induction may be focused on targeting some 
of the more general (ie not pathogen specific) signaling pathways that either 
positively or negative regulate autophagy (Deretic and Levine, 2009).  
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Potential mechanisms for P. gingivalis modulation of autophagy  
Our results have shown that P. gingivalis initially induces an increase in 
autophagosome number in macrophages which decreases over time. Since 
changes in autophagosome number (as indicated by levels of LC3-II) can 
indicate either an increase in autophagic activity or a block in autophagosome / 
lysosome degradation, we performed a series of experiments to assess 
autophagic flux in macrophages stimulated with P. gingivalis. We observed that 
P. gingivalis induced an initial increase in flux that dramatically decreased at later 
time points. Interestingly, at time-points where autophagic activity was at its 
lowest, P. gingivalis survival was at its greatest. These results do not provide 
answers for the mechanisms P. gingivalis utilizes to modulate autophagic flux in 
macrophages. Therefore, we are left with new opportunities for exploring the host 
cell signaling pathways and bacterial virulence factors that contribute to P. 
gingivalis manipulation of autophagy and bacterial survival.   
A number of pathogens that gain entry into host cells damage the bacteria 
containing vacuole in order to escape into the cytoplasm (Figure 43A-B) 
(Cemma and Brumell, 2012). Once in the cytoplasm, autophagy recognizes 
cytosolic bacteria by utilizing the ubiquitin conjugation system (Levine et 
al.,2011). Our recent preliminary studies with P. gingivalis have revealed that 
KGP gingipain activity contributes to the initial induction of autophagy activation 
that we observe in macrophages stimulated with P. gingivalis (Figure 43A-B). 
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Whether KGP activity contributes to membrane damage of P. gingivalis 
containing vacuoles or release of P. gingivalis into the cytoplasm remains to be 
determined. Furthermore, whether subsequent ubiquitination plays a role in P. 
gingivalis modulation of autophagy in macrophages remains unanswered. It is 
plausible that P. gingivalis may express an outer bacterial component to prevent 
ubiquination and subsequent trafficking to autophagosomes. In the case with 
Francisella, recent reports have shown that expression of O-antigen played a 
protective role against autophagy (Case et al.,2013). Francisella strains that lack 
the surface polysaccharide O-antigen are susceptible to autophagic capture upon 
entering the host cytosol, and consequently fail to survive. This is similar to 
Listeria (Yoshikawa et al.,2009) and Shigella (Dortet et al.,2011) which modify 
their surface by recruiting host proteins to mask themselves from autophagic 
recognition.  We have determined in this study that P. gingivalis expression of 
lipid A does not contribute to changes in autophagic activity. Whether other outer 
membrane components, other than lipid A, contribute to P. gingivalis intracellular 
trafficking and evasion of autophagy remain to be determined.  
The result that TLR2 signaling and P. gingivalis lipid A expression did not 
contribute to changes in autophagic activity were surprising due to the numerous 
reports documenting a role for TLRs (Xu et al.,2007; Delgado et al.,2008; Shi and 
Kehrl, 2008) and activation of the non-canonical autophagy pathway LAP in 
macrophages (Sanjuan et al.,2009; Mehta et al.,2014). Although these reports 
stress a role for TLRs in this process, it has now been shown that S. typhimurium 
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infection leads to LAP activation via recruitment of diacylglycerol to damaged 
bacterial containing vacuoles (Huang and Brumell, 2014). Therefore, the role for 
LAP in P. gingivalis modulation of autophagy in macrophages should not be ruled 
out (Figure 43C). Our findings thus far support a role for LAP in P. gingivalis 
infection for a couple reasons. As mentioned, LAP is utilized by phagocytes to kill 
and digest pathogens, which are usually extracellular (Sanjuan et al.,2009). 
Furthermore, due to the direct recruitment of autophagy proteins such as LC3, to 
the phagophore (Mehta et al.,2014), LAP is quick and transient, starting within 
the first 15m after TLR stimulation (Sanjuan et al.,2007). Our results show a 
similar trend, where there is a very quick increase in LC3 at 15 and 60m.  
Escape into the cytosol by vacuolar damage by gingipains or activation of LAP by 
some unknown bacterial component are two possibilities for how P. gingivalis 
may induce an initial increase in autophagy activation in macrophages (Figure 
43A-C). How then does P. gingivalis induce suppression of autophagy at later 
timepoints? Our results with the inhibitor of autophagosome / lysosomal fusion, 
bafilomycin, resulted in a significant increase in P. gingivalis survival at 3h, 
suggesting that P. gingivalis may suppress autophagy by blocking lysosomal 
fusion in order to survive in a non-acidic replicative niche (Figure 43D). If P. 
gingivalis survival dramatically decreased with bafilomycin treatment, this result 
would have suggested that this bacterium utilizes an acidic replicative niche for 
survival (Figure 43E), therefore P. gingivalis likely does not delay the fusion with 
lysosomes but rather induces a global block in autophagosome / lysosomal 
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progression. Additionally, if LAP is activated with P. gingivalis infection, it is 
possible that P. gingivalis may block phagosome / lysosomal fusion for 
intracellular survival (Figure 43F).  
One of the best-studied models for a pathogen that induces an initial increase 
then subsequent suppression of autophagy in host cells comes from studies with 
S. typhimurium (Huang and Brumell, 2014). S. typhimurium is targeted by the 
noncanonical pathway LAP for degradation; however, this pathogen can intercept 
the canonical autophagic pathway for survival. Whether degradation of S. 
typhimurium by LAP occurs before S. typhimurium manipulates canonical 
autophagy is unclear. Early after infection (about 1h), S. typhimurium containing 
vacuoles become damaged and the bacteria are exposed to the cytoplasm 
(Birmingham et al.,2006). Here the bacteria become ubiquitinated, and adapter 
proteins such as p62 are recruited and transfers cargo to autophagosomes 
(Zheng et al.,2009). Interestingly at 4h post infection, mTOR becomes 
redistributed to the S. typhimurium containing vacuole, which results in the 
inhibition of autophagy (Huang and Brumell, 2014). Clearly, this example with S. 
typhimurium highlights the complexities of bacterial interactions with the 
autophagic pathway. Whether P. gingivalis utilizes similar mechanisms to induce 
and then subsequently inhibit autophagy activity remains to be determined.  
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Figure 43. Potential mechanisms for P. gingivalis modulation of autophagy 
in macrophages. Our recent preliminary studies have shown that KGP gingipain 
activity contributes to the initial induction of autophagy by P. gingivalis in 
macrophages. Whether KGP gingipain activity activates autophagy by inducing 
membrane damage of the bacteria containing vacuole (B) and P. gingivalis 
escape into the cytoplasm remains to be determined (A). An unknown bacterial 
surface component may also be responsible for the initial increase we observed 
in LC3 II through activating the non-canonical autophagy pathway LAP (C). Our 
studies with bafilomycin suggest that P. gingivalis likely blocks autophagosome / 
lysosome fusion (D) to survive in a non-acidic replicative niche rather than 
delaying fusion with the lysosome (E) for survival within an acidic vacuole.  
Another possible mechanism for P. gingivalis suppression of autophagy may rely 
on blocking the fusion of lysosomes with phagosomes during active LC3 
associated phagocytosis (F).  
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Therapeutic strategies  
Targeting of inflammatory mediators 
Overproduction of proinflammatory mediators and dysregulated inflammasome 
activation has been reported to contribute to inflammatory pathology in a number 
of chronic diseases (Franchi et al.,2009; Davis et al.,2011; Dinarello, 2011). 
Although lipid deposition is considered a leading contributor to the inflammation, 
additional stimuli, such as infectious agents, have been considered as sources 
for the continuous inflammation (Rosenfeld and Campbell, 2011).  In our study, 
we observed infection with P. gingivalis induced low levels of proinflammatory 
mediators, particularly levels of IL-1β, from macrophages in vitro but accelerated 
chronic inflammatory atherosclerosis in vivo. These results would appear quite 
paradoxical considering the numerous reports documenting excessive 
inflammation to atherosclerosis progression. Thus, the question arises as to why 
a pathogen that induces low levels of inflammatory mediators would also be 
associated with chronic inflammatory atherosclerosis.  
 
IL-1β is a critical cytokine in host defense against a number of infectious agents 
(Mariathasan and Monack, 2007). Consequently, a number of pathogens have 
evolved mechanisms to prolong their survival by inhibiting IL-1β production 
(Taxman et al.,2010). Results from our study correlate with this notion since we 
observed low levels of IL-1β production were associated with P. gingivalis 
survival. Furthermore, utilizing a strain of P. gingivalis, expressing agonist lipid A, 
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induced high levels of IL-1β production and resulted in decreased bacterial 
survival, which correlated with decreased systemic vascular inflammation. 
Collectively, our results indicate that production of inflammatory mediators is 
protective against pathogen-mediated chronic inflammation, which is in 
agreement with our previous results that documented a protective role for TLR4 
in P. gingivalis-mediated chronic inflammation at systemic sites (Hayashi et 
al.,2012). Therefore, although activation of innate immunity is a necessity in 
clearing infections, there is a fine balance between activation of innate immunity 
and unresolved inflammation (Hansson and Libby, 2006; Tabas and Glass, 2013) 
Future therapies designed to inhibit excessive IL-1β levels associated with 
atherosclerosis should be designed with caution and should also consider the 
protective role of IL-1β. 
 
Supporting this concept, are results from a recent clinical trial for the 
inflammasome-mediated disease, cryopyrin-associated periodic syndrome 
(CAPS) (Koné-Paut and Piram, 2012).  Patients receiving the humanized 
monoclonal antibody, canakinumab, specific for neutralizing IL-1β, had a 67% 
increased risk for infection compared to 25% of patients in the placebo group 
(Tabas and Glass, 2013). This clinical trial supports the results presented in our 
study that highlight a protective role for activation of innate immunity against low-
grade chronic infection. An additional clinical trial was recently launched using 
canakinumab with the hypothesis that IL-1β inhibition will reduce major 
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cardiovascular events in patients with preexisting coronary artery disease (CAD) 
(Ridker et al.,2011). Our results demonstrate that the potential benefit of long-
term use of a neutralizing antibody to IL-1β in humans at high risk for 
atherosclerotic vascular disease must be substantial enough to counter the 
increased risk of infection. Therefore, we propose that it is imperative that future 
therapies consider the complexity of inflammatory pathways leading to chronic 
inflammation, particularly those that are accelerated by infection.   
 
Antagonizing / neutralizing TLR activation 
Continuous activation of TLR signaling pathways has been shown to be critical in 
progression of chronic inflammation (Cole et al.,2010a). Therefore, a number of 
therapeutics proposed for cardiovascular disease have focused on targeting 
TLRs (Cole et al.,2010b). Previously, it was proposed that common mechanisms 
of signaling via TLR2, TLR4 and MyD88 link stimulation by multiple pathogens 
and endogenous ligands to atherosclerosis progression (Michelsen et al.,2004). 
In support of these findings, a study demonstrated that activation of TLR4 by 
Chlamydia infection and lipids exacerbated atherosclerosis (Naiki et al.,2008). 
Therefore, it would appear that therapeutic antagonism would be beneficial for 
the treatment of chronic atherosclerosis (Leon et al.,2008). However, we 
revealed antagonism of TLR4 by P. gingivalis, through expression of a modified 
lipid A species, exacerbates atherosclerosis. These results suggest that 
therapies that have been designed to specifically antagonize TLR4 for the 
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treatment of atherosclerosis may not be successful. Although TLRs have been 
commonly associated with dentrimental effects in atherosclerosis, we now know 
the crucial protective role TLR signaling plays in clearing infection (Cole et 
al.,2013). We propose that future therapies designed to block TLR activation 
should be designed with caution due to the complexities in inflammatory 
pathways leading to atherosclerosis and ligand-specific pathways leading to 
disease progression.  
 
Autophagy 
Defects in autophagy machinery can worsen or directly contribute to various 
infectious diseases (Deretic, 2012a). Therefore, understanding signals that 
activate autophagy and molecular tags that guide autophagosomes to sequester 
invading pathogens has the potential to be an effective strategy for the treatment 
of infectious diseases (Choy and Roy, 2013). It is known that stimuli such as TLR 
stimulation (Xu et al.,2007; Delgado et al.,2008) can trigger antibacterial 
autophagy. An important finding from our study was TLR ligation did not play a 
role in P. gingivalis modulation of autophagy, therefore therapeutic intervention 
by TLR targeting of autophagy would most likely be unsuccessful with P. 
gingivalis infection. Therefore, it is likely that there will be different methods for 
autophagy activation that will be more effective than others for bacterial 
elimination (Choy and Roy, 2013).  
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Considering the variety of autophagic mechanisms that have been discovered to 
detect pathogens, there are likely multiple strategies utilized by pathogens to 
disrupt host autophagy that remain undiscovered (Deretic and Levine, 2009). 
Understanding these mechanisms will allow for effective approaches for targeting 
autophagy in order to counteract bacterial manipulation of this pathway. 
Discovering novel mechanisms for pathogen elimination by autophagy maybe 
particularly useful in cases where bacteria have evolved mechanisms to persist 
intracellularly and have become resistant to standard antibiotic treatments (Choy 
and Roy, 2013).  
 
Unfortunately, more questions than answers remain in regards to autophagy-
mediated clearance of bacterial pathogens, which demonstrates the need for 
further research in this area. To date, the role of autophagy in vivo has only been 
examined for only a few pathogenic bacteria (Zhao et al.,2007; Castillo et 
al.,2012) and it is currently unclear if these findings can be applied to a broad 
variety of different bacteria. Therefore, future studies will need to evaluate the 
relationship between specific bacteria and autophagy in order to determine which 
bacteria would be suitable for autophagic elimination and which specific 
mechanisms are involved in the complex interplay between bacterial infection 
and autophagy.  
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Chapter 8. Ongoing and Future Studies  
Our studies have revealed that P. gingivalis expression of antagonist lipid A 
results in evasion of host innate immunity at TLR4 and accelerated site-specific 
vascular inflammation. Furthermore, we have observed that P. gingivalis induces 
changes in autophagic activity in macrophages, which correlates with bacterial 
survival. These results add to our current knowledge on how P. gingivalis 
interacts with host innate immunity in order to exacerbate chronic inflammation. 
However, there are a number of unanswered questions that remain and are 
briefly mentioned below.  
 
Which autophagy pathways are activated with P. gingivalis infection?  
Engagement of TLRs has been shown activate the non-canonical autophagy 
pathway, LC3 associated phagocytosis (LAP) (Sanjuan et al.,2009; Mehta et 
al.,2014). However, TLR4 has been shown to serve as sensor for canonical 
autophagy (Xu et al.,2007; Wang et al.,2013). It is important to note, that non-
mutually exclusive pathways can be active in response to a single pathogen at a 
given time (Levine et al.,2011; Huang and Brumell, 2014). Whether canonical 
and / or non-canonical pathways are active with P. gingivalis infection remain 
unanswered. Our results thus far suggest that TLRs are not involved. We 
revealed that TLR2 signaling only played a minor role while increased 
immunostimulatory activity at TLR4, by PG1587381, played no role in P. 
gingivalis-mediated induction of autophagy in macrophages.  Additional studies 
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performed by a colleague in the laboratory suggest that the adaptor protein 
MyD88 is not involved. These findings leave us with new opportunities for 
investigating the host cell signaling pathways that lead to autophagy activation / 
subsequent suppression in macrophages stimulated with P. gingivalis.  
 
Our work thus far would suggest that LAP is likely not activated in macrophages 
stimulated with P. gingivalis. Future studies to further investigate the role of LAP 
will utilize BMDM from ULK1 deficient mice. ULK1 is a component of the 
autophagy pre-initiation complex and is dispensable for LAP (Sanjuan et 
al.,2009). Therefore, if we observe changes in P. gingivalis-mediated induction / 
suppression of autophagy in ULK1-/- BMDM versus wild-type BMDM this would 
suggest that canonical autophagy is exclusively involved with P. gingivalis 
infection. Furthermore, electron microscopy can be used to observe either the 
double membrane autophagosomes (that are associated with canonical 
autophagy) or only the single membrane structures (that are associated with 
LAP) (Sanjuan et al.,2009).   
 
Which virulence factors are involved with P. gingivalis-mediated changes 
in autophagy? 
Since expression of lipid A does not appear to be playing a role in P. gingivalis 
mediated changes in autophagic flux, we have begun to evaluate the role of 
another virulence factor expressed by P. gingivalis, gingipains. Gingipains are 
cysteine proteases that are either cell membrane associated or excreted as 
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soluble proteins (Madrigal et al.,2012). Gingipains are critical to P. gingivalis 
virulence due to the observation that these proteins have been attributed to the 
cleavage of a number of host proteins (Mikolajczyk-Pawlinska et al.,1998) in 
order to dampen host innate immunity. It was originally proposed that ginipains 
are secreted by a Type IV secretion mechanism  (Genco et al 1999), however it 
has now been determined that a Type IX secretion system may be involved 
(Nakayama, 2015).  
 
A number of pathogens that are equipped with secretion systems have been 
shown to modulate autophagy. For example, L. pneumophila induces autophagy 
in infected mouse macrophages in a manner that is dependent on the bacterial 
type IV secretion system (Cemma and Brumell, 2012) Furthermore, it was shown 
recently that L. pneumophila avoids autophagy targeting during infection by the 
production of a type IV Secretion system effector, RavZ (Huang and Brumell, 
2014). Burkholderia pseudomallei utilizes a Type III Secretion system to escape 
from the phagosome into the cytosol (Gong et al.,2011). Our recent preliminary 
findings with P. gingivalis reveal that gingipains play a role in the initial induction 
of autophagy we observe in macrophages at 60’, but had no effect on P. 
gingivalis suppression of autophagy at later timepoints (3h). These results were 
specific for KGP activity and independent of RGP. Therefore, future studies will 
further assess the role of KGP activity on P. gingivalis induction of autophagy 
and whether this induction plays a role in bacterial survival.  
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What is the role of P. gingivalis evasion of TLR4 signaling in monocytic 
cells on site-specific vascular inflammation? 
Our previous studies have reported that global deficiency of TLR2 results in 
diminished P. gingivalis-induced vascular inflammation (Hayashi et al.,2010b) 
whereas global deficiency of TLR4 exacerbated the response (Hayashi et 
al.,2012). These results suggested that signaling through TLR4 might have a 
protective role in P. gingivalis-induced inflammation at systemic sites. By utilizing 
the lipid A mutant strains we observed that P. gingivalis expression of antagonist 
lipid A resulted in progressive vascular inflammation while expression of agonist 
lipid A did not, further supporting a protective role for TLR4 at systemic sites. 
These results leave us with new areas of exploration for the specific cell types 
that are involved in this response. Our in vitro studies with macrophages have 
revealed that expression of antagonist lipid A contributes to P. gingivalis evasion 
of the inflammasome, attenuated pro inflammatory mediators and bacterial 
survival. Whether the ability of P. gingivalis to evade / antagonize immune 
detection by macrophages at TLR4 contributes to chronic inflammation in vivo 
remains undefined. Therefore, in future studies we will utilize monocyte-specific 
deletions of TLR4 in ApoE mice (ApoE-/-TLR4 f/f LysM-Cre+ mice and ApoE-/-
TLR4 f/f LysM-Cre-) to define cell-type specificity in P. gingivalis evasion of host 
immunity at TLR4 on chronic inflammation. We would expect that ApoE-/-TLR4f/f 
LysM-Cre+ mice infected with P. gingivalis 381 and the lipid A mutant strains to 
have enhanced vascular inflammation compared to ApoE-/-TLR4 f/f LysM-Cre-. 
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We postulate the enhanced inflammatory phenotype is due to a deficiency in 
protective TLR4 signaling from the myeloid lineage.  
 
Interestingly, our results revealed that expression of lipid A did not play a role in 
oral bone loss, which is in agreement with our previous report that demonstrates 
P. gingivalis inflammatory bone loss is independent of TLR4 signaling. 
Hajishengallis et al. recently reported that a change in the oral microbial 
community is essential for P. gingivalis induced oral bone loss (Hajishengallis et 
al.,2011). Therefore, although we did not observe changes in oral bone loss in 
our model between wild-type P. gingivalis and the lipid A mutants, the role of the 
oral microbiome in this response has not been examined. In a rabbit model of 
periodontitis, the Darveau laboratory has recently reported that lipid A 
phosphatases are required for P. gingivalis colonization and commensal 
overgrowth (Zenobia et al.,2014). Although wild-type and lipid A bacterial 
mutants all induced oral bone loss, the abundance and species of oral bacteria 
that resulted were different, indicating that disruption of normal oral flora was 
sufficient to induce disease. Therefore, future studies in collaboration with the 
Darveau laboratory, will investigate the ability of P. gingivalis lipid A mutant 
strains to alter the amount or composition of the oral microbiome. Based on our 
studies and studies in the rabbit model we would anticipate that mice infected 
with 381 and the lipid A mutants would develop different oral microbiota that 
impacts the induction of oral bone loss.  
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What is the role of P. gingivalis suppression of autophagy in monocytic 
cells on vascular inflammation? 
Autophagy has been shown to play a protective role against infection with a 
number of intracellular pathogens (Levine et al.,2011). The Deretic group 
demonstrated that autophagy suppresses M. tuberculosis growth and damaging 
inflammation (Castillo et al.,2012).  In contrast, a number of pathogens infiltrate 
autophagosomes to promote their survival and replication (Colombo, 2005; Choy 
and Roy, 2013; Huang and Brumell, 2014). We determined that P. gingivalis 
suppresses autophagy in monocytic cells and this correlated with bacterial 
survival. While these studies point to a role for autophagy in P. gingivalis 
bacterial persistence, the role of P. gingivalis suppression of autophagic 
clearance in monocytic cells and how this contributes to vascular inflammation 
remains uncharacterized.  
 
Analogous to P. gingivalis evasion of TLR4 signaling, we propose that P. 
gingivalis suppression of autophagy in monocytic cells, functions in dissemination 
of the pathogen and immune activation at systemic sites. In future studies we will 
utilize monocyte-specific deletions of Atg5 in ApoE-/- mice (ApoE-/-Atg5 f/f LysM-
Cre+ and ApoE-/-Atg5 f/f LysM-Cre-). We expect that infection of ApoE-/-Atg5 f/f 
LysM-Cre+ mice infected with 381 will result in decreased vascular inflammation 
compared to ApoE-/-Atg5 f/f LysM-Cre- mice infected with P. gingivalis 381, since 
our in vitro studies have revealed that P. gingivalis suppression of autophagy 
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promotes bacterial survival. On the other hand, uncontrolled inflammation in a 
number of inflammatory diseases has been linked to defective autophagy (Levine 
et al.,2011; Deretic et al.,2013) and autophagy has been shown to regulate 
inflammasome activation (Harris et al.,2011; Nakahira et al.,2011; Zhou et 
al.,2011). Thus, it is possible that we could observe increased vascular 
inflammation in ApoE-/-Atg5 f/f LysM-Cre+ mice infected with 381.  
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